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Keele, UK
3Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
4Department of Gastroenterology, University College Hospital, London, UK
5Department of Histopathology, University College Hospital, London, UK
*Corresponding author s.halligan@ucl.ac.uk
Background: Identification of biomarkers that predict severe Crohn’s disease is an urgent unmet
research need, but existing research is piecemeal and haphazard.
Objective: To identify biomarkers that are potentially able to predict the development of subsequent
severe Crohn’s disease.
Design: This was a prognostic systematic review with meta-analysis reserved for those potential
predictors with sufficient existing research (defined as five or more primary studies).
Data sources: PubMed and EMBASE searched from inception to 1 January 2016, updated to
1 January 2018.
Review methods: Eligible studies were studies that compared biomarkers in patients who did or
did not subsequently develop severe Crohn’s disease. We excluded biomarkers that had insufficient
research evidence. A clinician and two statisticians independently extracted data relating to predictors,
severe disease definitions, event numbers and outcomes, including odds/hazard ratios. We assessed
risk of bias. We searched for associations with subsequent severe disease rather than precise estimates
of strength. A random-effects meta-analysis was performed separately for odds ratios.
Results: In total, 29,950 abstracts yielded just 71 individual studies, reporting 56 non-overlapping cohorts.
Five clinical biomarkers (Montreal behaviour, age, disease duration, disease location and smoking), two
serological biomarkers (anti-Saccharomyces cerevisiae antibodies and anti-flagellin antibodies) and one
genetic biomarker (nucleotide-binding oligomerisation domain-containing protein 2) displayed statistically
significant prognostic potential. Overall, the strongest association with subsequent severe disease was
identified for Montreal B2 and B3 categories (odds ratio 4.09 and 6.25, respectively).
Limitations: Definitions of severe disease varied widely, and some studies confounded diagnosis and
prognosis. Risk of bias was rated as ‘high’ in 92% of studies overall. Some biomarkers that are used
regularly in daily practice, for example C-reactive protein, were studied too infrequently for meta-analysis.
Conclusions: Research for individual biomarkers to predict severe Crohn’s disease is scant,
heterogeneous and at a high risk of bias. Despite a large amount of potential research, we encountered
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relatively few biomarkers with data sufficient for meta-analysis, identifying only eight biomarkers with
potential predictive capability.
Future work: We will use existing data sets to develop and then validate a predictive model based on
the potential predictors identified by this systematic review. Contingent on the outcome of that
research, a prospective external validation may prove clinically desirable.
Study registration: This study is registered as PROSPERO CRD42016029363.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 25, No. 45. See the NIHR Journals Library website for further project information.
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Crohn’s disease causes inflammation of the intestines. Traditional treatment uses drugs, such assteroids, at a gradually increasing dose as symptoms worsen. Newer ‘biological’ drugs may stop
disease, but are not used as an early treatment because they are expensive and have serious side
effects. Using biologicals early means knowing which patients will develop severe disease in the future.
A ‘prognostic biomarker’ is a measurement made on a patient that predicts a future outcome. A lot of
research has attempted to identify biomarkers that predict severe Crohn’s disease, but research is
haphazard and of variable quality. We therefore carried out a ‘systematic review’, which identifies
research in a comprehensive and unbiased fashion. We found nearly 30,000 research papers, 71 of
which were acceptable quality and described 56 groups of Crohn’s disease patients. We then used a
statistical method called ‘meta-analysis’ to combine results from multiple studies. This allowed us to
identify the most promising biomarkers to predict future severe disease. We found five clinical
biomarkers (e.g. age and smoking), two blood biomarkers and one genetic biomarker that seemed
reasonably able to predict future severe Crohn’s disease.
However, we also found that most research was poorly performed and frequently confused diagnosis
(current disease) with prognosis (future disease). Some commonly used biomarkers were not sufficiently
investigated. We were surprised to identify so few prognostic biomarkers in the face of a seemingly vast
amount of research.
Future research should be better conducted and not confuse diagnosis with prognosis. We will use
statistical methods to combine the promising biomarkers that we identified into a ‘prognostic model’,
which is a mathematical formula that provides the likelihood of developing severe disease in the future.
We will then test how well this works by using patient data from existing Crohn’s disease databases.
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The research detailed in this monograph arose from the National Institute for Health Research Health
Technology Assessment programme call HTA 14/210: ‘Prognostic markers in early Crohn’s disease’.
The need for this research turns on the understanding that early administration of biological therapies
to patients with Crohn’s disease may prevent disease progression. Indiscriminate administration of
biologicals to all patients with a new diagnosis of Crohn’s disease would not, however, be sensible
because these drugs are both expensive and associated with serious side effects in a small but
significant number of patients. Administering biologicals to patients whose disease is destined to be
indolent would necessitate extensive over-treatment. Therefore, the unmet need is for a tool that
accurately predicts those patients with a new diagnosis of Crohn’s disease whose disease is destined
to become severe at some point in the future. Biological therapy could be targeted to this group of
patients and over-treatment avoided elsewhere. This approach would also probably be cost-effective.
A ‘prognostic biomarker’ is a measurement made on a patient that predicts a future event, for example a
biological process and/or health state. Biomarkers may also be ‘diagnostic’, that is their level represents
a current health state, for example the presence or absence of active disease. Some biomarkers may be
both diagnostic and prognostic. The primary objective of this research was to perform a comprehensive
systematic review across all biomarker types used for Crohn’s disease (e.g. clinical, serological, genetic,
radiological, endoscopic and histological), with the aim of identifying those that display potential
prognostic capability for prediction of subsequent severe disease.
Review methods
The review was registered (PROSPERO CRD42016029363) and the protocol published. Following a
scoping search, a clinical researcher experienced in systematic review and multidisciplinary Crohn’s
disease management designed and performed the search, supervised by co-researchers, including
statisticians with extensive prior experience of prognostic systematic reviews, methodology experts
and disease experts. Using an inclusive strategy, our search string combined five clusters of terms to
identify (1) Crohn’s disease, (2) severe disease, (3) biomarkers, (4) terms to identify prediction/prognosis
and (5) exclusion criteria (e.g. animal research and narrative reviews). Hand-searching was also adopted.
The PubMed and EMBASE databases were searched from inception to 1 January 2016, with an update
carried out up to 1 January 2018 for serological biomarkers. The target condition was human Crohn’s
disease, confirmed by standard criteria. There was no age restriction, with paediatric subgroups
identified where possible, and no language restriction. We anticipated finding a plethora of potential
biomarkers and set a priori quality/quantity thresholds to prevent including biomarkers with insufficient
primary evidence for sensible meta-analysis, stipulating that predictors should be reported in at least
five individual studies. We excepted new but exceptionally promising predictors, which were chosen by
an expert panel from a list of all candidates identified by the review. The panel also indicated predictors
that were already widely used. Given that no generally accepted definition of ‘severe’ disease exists,
we used a broad range of criteria to avoid discarding potentially valuable research. We stipulated a
minimum 3-month duration between biomarker measurement and outcome to ensure that the data
were prognostic rather than diagnostic.
Full-text articles were examined by Darren Boone and queries were raised with other collaborators.
Ultimately, Sue Mallett examined all full-text articles selected for the review and verified data
extraction. Data were extracted into a data sheet that included author, journal, design (e.g. cohort,
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randomised controlled trial and retrospective database), methods, setting/context (organisation/service
type and country), participants (including age range and gender), time since diagnosis (symptom
duration and/or time since diagnosis for established disease), markers of severe disease, symptom
severity, disease location and burden, disease complications, Crohn’s activity indices, surgical details,
perianal disease and continence outcomes. In addition, we extracted data specific to the prognostic
marker investigated, including measurement (methods, frequency), adverse events, reliability and
reproducibility, and costs, where available. We recorded study interventions and outcomes (including
definitions, thresholds for severity/remission and whether or not these thresholds were prespecified in
the publication) and median follow-up time with interquartile range. For models, we documented study
type (development, internal/external validation), included predictors (including measurement methods,
categorisation of continuous outcomes, blinding to outcome assessment and predictor variables), sample
size (number of participants with events and included in modelling), statistical modelling methods
(including fitting, missing data treatment and methods to adjust for overfitting), model performance
(discrimination, calibration, sensitivity, specificity, net benefit and reclassification), model estimates and
95% confidence intervals (e.g. univariable unadjusted or adjusted estimates for predictors, adjusted
coefficients for predictors in multivariable models). Where available, we extracted estimates with
95% confidence intervals including odds ratios, risk ratios and hazard ratios. The risk of bias for each
included study was assessed via PROBAST (Prediction study Risk Of Bias ASsessment Tool). Domains
were combined to give an overall risk of bias.
Where possible, participants with and without severe disease were extracted into 2 × 2 contingency
tables. Studies were grouped for meta-analysis by effect estimates (e.g. odds ratios and hazard ratios)
and meta-analysis was considered when there were three or more individual studies of a biomarker
from which data using the same effect estimate could be extracted. We searched for predictor
association with subsequent severe disease rather than exact estimates of strength or interpredictor
comparisons. Studies were grouped for meta-analysis by prediction estimate type and by definition of
severe disease, where possible. We grouped studies that were ‘adequately adjusted’, defined by clearly
reported adjustment factors. Each study was included once per meta-analysis; where studies reported
more than one estimate from the same participants using different definitions of severe disease, we
selected the highest ranking. For example, estimates reporting surgery are preferentially included for
meta-analysis as a higher-ranked estimate. Random-effects inverse variance meta-analysis was used
to pool odds ratios. Meta-analysis was performed using ‘metan’ (Stata 14, StataCorp LP, TX, USA)
because 2 × 2 contingency tables were not always available. Results were analysed across all ages,
with groupings indicated on forest plots.
Results
A total of 29,947 abstracts were identified: 15,923 duplicates were removed and 14,024 abstracts were
screened. In total, 247 full-text articles were assessed. Ultimately, 71 articles were included in the review,
describing 56 non-overlapping patient cohorts. This included the addition of C-reactive protein, which
was deemed important by the expert panel (other predictors identified by the panel were either already
included or yielded insufficient data for meta-analysis). Most studies were European (37/71, 52%), with
14 (20%) studies from the USA/Canada. Forty (56%) studies were multicentre. In total, 36 (51%) studies
were prospective, 33 (46%) were retrospective and two (3%) were unclear. Of the 71 studies, 11 (16%)
were paediatric only, 23 (32%) were adult only and 37 (52%) were mixed. Recruitment dates varied, with
22 (31%), studies not reporting dates; follow-up also varied (median 8 years, interquartile range 5–10 years,
range 0.8–18 years). Studies frequently presented several different definitions of severe disease. Most of
the studies were rated as being at high risk of bias in at least one domain. Accordingly, ‘Overall risk of
bias’ was rated as being ‘high’ in 65 (92%) studies. Only three studies were rated as being at a ‘low’ risk of
bias. Overall, we identified 12 individual predictors that were eligible for meta-analysis: three serological,
one genetic and eight clinical. There were no radiological, endoscopic or histological predictors that met a
priori criteria for inclusion.
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We were able to meta-analyse seven clinical markers from 58 studies. These were Montreal disease
behaviour, age, disease duration, disease location, smoking, sex and family history. Meta-analysis of
12 studies (4376 participants, 1551 events) found that B2 stricturing, B3 fistulating, and either severe
or disabling disease predicted severe disease more powerfully than B1 inflammation alone. B2 and
B3 Montreal disease behaviours were the strongest predictors of subsequent severe disease in our
review (B2: odds ratio 4.09, 95% confidence interval 2.59 to 6.48; B3: odds ratio 6.25, 95% confidence
interval 3.68 to 10.63). Age at diagnosis was examined in 43 studies (19,623 participants, 7010 events).
Most studies categorised age using Montreal/Vienna thresholds, so data were greatest for three groups:
< 17 years, 17–40 years and > 40 years. Overall, diagnosis at < 17 years was associated with lower risk of
subsequent severe disease than other ages. Disease duration was examined in 14 studies (8690 participants,
1714 events). Meta-analysis found that increased disease duration was associated with significant risk of
subsequent severe disease at all durations examined. Disease location was examined in 32 studies (10,877
participants, 4193 events). Studies were diverse regarding the segments and/or segment combinations
described.We were able to analyse ‘colonic disease alone’ and ‘any colonic disease’ versus other locations.
Overall, colonic disease alone conferred significantly lower surgery risk (odds ratio 0.42, 95% confidence
interval 0.31 to 0.58). Similarly, any colonic disease (23 studies, 7373 participants, 3086 events) predicted
lower surgical or B2/B3 risk than no colonic disease. Perianal disease (24 studies, 13,483 participants, 5510
events) was associated with significantly increased risk of subsequent severe disease overall (1.84 odds ratio,
95% confidence interval 1.29 to 2.62). A total of 34 studies reported smoking associations (11,475
participants, 5097 events); meta-analysis of 26 studies found that current smoking increased risk
significantly (odds ratio 1.53, 95% confidence interval 1.30 to 1.79). Sex was examined in 35 studies
(14,489 participants, 5350 events) and was not a significant predictor overall. Family history was
examined in 18 studies (5687 participants, 1413 events). Meta-analysis found no consistent direction
and no significant association (odds ratio 1.05, 95% confidence interval 0.81 to 1.36).
Three serological markers (anti-Saccharomyces cerevisiae antibodies, anti-flagellin antibodies and
C-reactive protein) from 13 studies were meta-analysed. Anti-Saccharomyces cerevisiae antibodies
and anti-flagellin antibodies showed potential prognostic association. Anti-Saccharomyces cerevisiae
antibody-positive patients had significantly increased odds of developing severe disease (odds ratio
2.29, 95% confidence interval 1.31 to 3.99, six studies). Anti-flagellin antibody data were identified in
five studies; meta-analysis from odds ratios did not reach significance, but additional evidence from
hazard ratios indicated significant association. For C-reactive protein, data were identified from only
three studies (the expert panel requested C-reactive protein to be included) and the results found no
significant predictive association. Of the genetic markers, results for nucleotide-binding oligomerisation
domain-containing protein 2 (NOD2) in at least one variant were reported in 17 studies, although one
study reported only p-values and was excluded from meta-analysis. Meta-analysis of 16 studies
(5407 participants, 2645 events) suggested higher risk with a NOD2 variant gene overall (odds ratio
1.69, 95% confidence interval 1.43 to 2.00).
Conclusions
During this review, we identified seven previous systematic reviews investigating the association
of mostly serological and some genetic biomarkers with severe Crohn’s disease. Three of these did
not separate primary studies of diagnosis and prognosis. One review identified two studies of
predictive biomarkers, one of which was also identified as the only prognostic study by a second
review. The remaining systematic review included three biomarker prediction studies, only one of
which met our inclusion criteria.
In summary, despite prognostic research being declared the greatest unmet need in Crohn’s disease
research and being faced with a vast amount of potential research, we could identify relatively few
prognostic studies; just 56 non-overlapping patient cohorts were identified. Although a multitude
of biomarkers were investigated, relatively few were examined individually in sufficient depth and
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breadth for meta-analysis. Although genetic and serological biomarkers are perceived by clinicians as
‘cutting edge’, the reality is that we could identify only three that appeared genuinely prognostic:
two serological (increased risk of developing severe disease was associated with anti-Saccharomyces
cerevisiae antibodies and anti-flagellin antibodies positivity) and one genetic (NOD2 variant gene
positivity conveyed increased risk of developing severe disease). At the time of writing, this should
help reassure clinicians that lack of access to novel biomarkers is not a major clinical disadvantage.
We were able to identify five clinical biomarkers that appeared prognostic; the following were
associated with increased risk of developing severe disease: Montreal B2/B3 disease behaviour versus
B1, diagnosis at > 17 years of age, increased disease duration, disease beyond the colon and smoking.
Limitations
Our study does have limitations, predicated primarily by the quality of existing data. As noted already,
despite being faced with a vast amount of potential research, we could identify relatively few prognostic
studies. This paucity of genuine prognostic studies raises the possibility that our research is missing
some clinically useful predictors simply because they have not been sufficiently studied (and so were
discarded by our a priori quality criteria). This was the case for novel genetic and serological markers,
the large majority of which were not studied by a sufficient number of primary studies to be eligible.
Moreover, we were surprised that many apparently common predictors were not examined in sufficient
depth; faecal calprotectin is one example. Furthermore, of those studies we were able to include, the
majority were at high risk of bias, which will exert an effect on their results and, therefore, on the
findings from our meta-analysis. A major frustration was that studies frequently confounded diagnosis
and prognosis, which meant that our extraction was problematic.
There is also considerable existing excitement around multigene assays [e.g. PredictImmune Ltd
(Cambridge, UK)] to predict severe disease, but these had been studied insufficiently for inclusion in
our review and so could not be meta-analysed. Their recommendation will require either reporting in
sufficient primary studies to allow meaningful meta-analysis or the publication of a prospective study
of methodological quality such that meta-analysis of smaller, less rigorous studies becomes unnecessary.
Future work
The issue now turns to how to apply this review to the benefit of individual patients. Using existing
data sets to which we have access, we are currently developing and validating a multivariable
prognostic model that will combine the predictive factors identified so as to provide an estimate of the
risk of subsequent severe disease for patients presenting with a new diagnosis of Crohn’s disease. For
obvious reasons, the model will not be applicable to those patients who present with severe disease.
Contingent on the results of this validation, it may be clinically useful to perform an external validation
in UK centres. In the meantime, we suggest that considerably more prognostic research in this area
is required. The quality of this research and any multivariable models that arise should be improved by
enhanced methodological rigour and adherence to the TRIPOD (Transparent Reporting of a multivariable
prediction model for Individual Prognosis Or Diagnosis) reporting guidelines.
Study registration
This study is registered as PROSPERO CRD42016029363.
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The research detailed in this monograph is a response to the National Institute for Health Research(NIHR) Health Technology Assessment (HTA) programme call of 2014, HTA 14/210, ‘Prognostic
markers in early Crohn’s disease’. Some of the text presented in this section has been published
previously as part of the study protocol.1
The commissioning brief stated that the NHS decision problem turned on the fact that:
Some patients with Crohn’s disease follow a relatively limited course with rapid response to relatively
simple treatment and few subsequent acute flare-ups. Others progress rapidly to severe disease needing
escalation of medical treatment or surgery: as many as one-third of patients require surgery within a year
of beginning oral steroids. Rapid disease control may allow sufferers to return to work and other normal
activities more rapidly and may reduce the need for surgery. NICE [National Institute for Health and Care
Excellence] does not currently recommend early use of anti-TNF [tumour necrosis factor] drugs although
there is some evidence of better early outcomes with their use. Rapid escalation of medical treatment
is allowed for within current NICE guidelines. Identification of patients who might benefit from early
intensive treatment is needed before the cost-effectiveness of treatment strategies can be determined.
Reproduced with permission, 2021, NIHR HTA programme2
The HTA programme stipulated that the commissioned research should comprise a systematic review
that evaluated ‘clinical criteria for treatment and/or use of biomarkers or biopsy informatics to develop
a clinical tool to identify patients most likely to benefit from early intensive treatment’. Outcomes of
the research would therefore be ‘[a]n overview of current evidence’ combined with ‘a signal as to which
biomarkers may be most useful’. It was also noted that, contingent on the findings, any prediction tool
that was developed during the research may be subsequently tested in a prospective study, in research
commissioned by the HTA programme.
Crohn’s disease and modern treatment strategy
This section is reproduced with permission from Halligan et al.1 This is an Open Access article distributed
in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original
work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below includes minor
additions and formatting changes to the original text.
Crohn’s disease is an inflammatory ulcerative enteropathy that generally affects young adults and
can be extremely debilitating. There is no cure and treatment is traditionally applied in a ‘bottom-up’
fashion, aimed at treating symptoms as and when they arise, with treatment escalated when symptoms
worsen. However, newer biological therapies appear to ameliorate the ultimate disease trajectory in
addition to treating symptoms. This attribute raises the possibility that adopting these agents early in a
‘top-down’ paradigm could ‘stop the disease in its tracks’. The first disease-modifying biological agent was
infliximab, which is a monoclonal antibody against the cytokine tumour necrosis factor (TNF) alpha that
binds with it and prevents receptor binding. A randomised trial of infliximab versus placebo found that,
of those patients who responded to an initial dose, half achieved complete mucosal healing after 1 year
and stayed in remission longer and discontinued steroids earlier than control patients.3 Biologicals also
appear incrementally more effective when used in combination with other immunomodulators, such as
azathioprine,4 especially when administered in a ‘top-down’ fashion.5,6 Newer agents, such as adalimumab,
are also effective.7
DOI: 10.3310/hta25450 Health Technology Assessment 2021 Vol. 25 No. 45
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Halligan et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
1
The REACT (Early combined immunosuppression for the management of Crohn’s disease) study
randomised patients to either conventional ‘bottom-up’ therapy or ‘early combined immunosuppression’
and found that major complications, hospitalisation and surgery were significantly reduced at 24 months
for the intervention clusters.8 Accordingly, current thinking is that early aggressive biological treatment
combined with immunomodulation will prevent future disease and is preferable to merely responding
to symptoms. However, administering biologicals early to all patients is unwise because these agents
may precipitate serious infection, are hepatotoxic and can cause demyelination, lupus syndrome and
lymphoma.9 Biologicals are also very expensive. A strategy that could identify new diagnoses of Crohn’s
disease who are destined to develop into severe disease in the future would have considerable clinical
utility through ‘personalised and targeted therapy’, that is directing these patients to early biological
treatment while avoiding unnecessary over-treatment in others.
Diagnostic and prognostic biomarkers of disease activity
According to the US National Institutes of Health, a biomarker is a measurable characteristic that
indicates a biological process that may reflect pathology and pharmacological response to treatment.10
Biomarkers in Crohn’s disease may indicate the presence or absence of disease, as well as its severity.
It is also important to understand the distinction between a ‘diagnostic’ biomarker and a ‘prognostic’
biomarker. While a reliable diagnostic biomarker may reflect the presence/absence/severity of current
disease, a prognostic biomarker may reflect the presence/absence/severity of future subsequent
disease (or of response to therapy, etc.). A clinically useful biomarker may be diagnostic, prognostic or
a combination of both.
In our research, we have not been too restrictive when labelling an intervention or characteristic as a
‘biomarker’. Although the term is associated with novel diagnostic technologies, simple and effective
biomarkers have been used for decades. For example, stool frequency directly reflects colonic
inflammation and should not be excluded from systematic review simply because it is not perceived as
‘novel’. Smoking is believed to have a profound effect on disease outcome and should also be included,
although smoking in and of itself is not a marker of disease activity. Several studies have investigated
simple clinical factors that are predictive of an ‘aggressive’ disease course and Markov modelling of
these factors has shown that disease activity over the year following diagnosis is predictive of the
clinical course of the disease over the following decade.11
For the commissioned research we, therefore, aimed to identify the whole range of potential
biomarkers used in Crohn’s disease, including clinical (both clinician and self-reported outcomes),
endoscopic, radiological, faecal, urinary, serological (including the range from basic tests to antibodies),
genetic and histological biomarkers. For example, C-reactive protein (CRP) is an acute-phase protein
expressed by the liver that is widely used in clinical practice. Calprotectin, a protein that is released in
inflamed gut epithelium, is a more recent biomarker that has also reached daily practice. Calprotectin
levels change with treatment. Lactoferrin is a similar protein biomarker. The diagnostic accuracy of
such biomarkers has already been subject to systematic review and meta-analysis. For example, one
such review12 aimed to determine if calprotectin levels could differentiate between inflammatory and
irritable bowel disease in children.
BACKGROUND
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Chapter 2 Research questions
Our overarching research question was to identify biomarkers that are potentially able to predictwhich patients with Crohn’s disease are destined to subsequently develop severe disease.
This question (and related others) was answered through the research objectives listed below.
Primary research objective
1. To carry out a systematic review of the literature, including meta-analysis where possible, that
covers all potential biomarker areas to assess their predictive capability for severe Crohn’s disease.
This review will determine the breadth, depth and quality of currently available evidence, and
meta-analysis will identify which biomarkers may be sufficiently predictive for use in a subsequent
prognostic model.
Secondary objectives
1. To compare potential predictors by direct and indirect comparison of study results. Direct
comparisons between predictors from the same study constitute stronger evidence and will be
preferred over indirect comparisons across different studies.
2. To explore heterogeneity among studies.
3. To identify those predictors that appear useful for the development and validation of a prognostic
model to identify patients who are destined to develop severe Crohn’s disease.
4. To examine and validate any existing models identified by the systematic review.
The ability to examine primary and secondary objectives will be highly dependent on the availability
and quality of data from published studies.
DOI: 10.3310/hta25450 Health Technology Assessment 2021 Vol. 25 No. 45
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Halligan et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
3

Chapter 3 Review methods
At the design stage, we anticipated that there would be many potential biomarkers, which couldmake for an unwieldy review. We, therefore, set a priori quality/quantity thresholds for review
inclusion to prevent extraction of data for biomarkers that have not been sufficiently studied for the
findings to be deemed generalisable/reproducible and/or that have weak methodology. For example, at
the time of writing the review protocol, more than 70 separate genes had been implicated in Crohn’s
disease.13 Given that genetic sequencing is currently very expensive and there are multiple potential
individual genetic predictors, we anticipated that few genetic predictors will have been studied in
sufficient depth. However, sequencing will probably become increasingly cost-effective in the near
future. Our systematic review, therefore, considered only those genes for which sufficient primary
studies exist to provide a useful signal of their prognostic potential.
Genetic makeup is also linked to response to biological therapy. Given that genetic makeup is fixed,
these factors need to be measured only once (in contrast to other biomarkers that fluctuate with
disease activity). There are also multiple antibody candidates, and prognostic strategies have focused
on both titres of individual antibodies and the number of different antibodies. For example, patients
with three or more positive antibodies are eight times more likely to need surgery than patients who
are antibody negative.14
Ethics review
Ethics permission is not required by our institution for systematic review of available medical literature.
Search strategy
The protocol for this research was published.1 Our review question(s) and data extraction were guided
by the CHARMS (CHecklist for critical Appraisal and data extraction for systematic Reviews of
prediction Modelling Studies) checklist.15 Darren Boone, a clinical researcher experienced in systematic
review and multidisciplinary Crohn’s disease management, designed and carried out the search and
was supervised by co-researchers, including statisticians with extensive prior experience of systematic
review of prognostic markers (LA and SM), methodology experts (SH and SM) and disease experts
(SH, TA, SB, MRJ and SAT). Uncertainties were resolved by face-to-face discussion.
Our scoping search found that individual studies frequently reported combinations of predictive
biomarker groups.1 For example, articles primarily reporting genetic predictors often included
serological and/or clinical predictors. Therefore, we adopted an inclusive search strategy to identify
all potential biomarker groups for severe Crohn’s disease. We combined five clusters of search terms:
(1) identification of Crohn’s disease research; (2) identification of severe, disabling or complicated disease;
(3) a panel of candidate biomarkers; (4) a panel of keywords and medical subject headings (MeSH) to
identify prediction/prognosis; and (5) a panel of headings to exclude animal research, narrative reviews
and editorials. Searches were combined using Boolean operators.We then tested the search string
through its ability to identify key papers that were nominated by the authors. If unidentified, article
keywords and MeSH were interrogated and the search string was refined until papers were captured.
The search string used is shown in Table 1.
Search terms were identified by hand-searching Crohn’s literature and guidelines from established
clinical associations [e.g. the European Crohn’s and Colitis Organisation (Vienna, Austria), the European
Society of Gastrointestinal and Abdominal Radiology (Vienna, Austria)], and via a multidisciplinary panel.
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Search process
Using the search string, Darren Boone queried the PubMed and EMBASE databases for literature
published from inception to 1 January 2016 and screened the titles and abstracts of identified primary
studies to assess their eligibility. Grey literature was identified by hand-searching conference proceedings
from 2012–15, inclusive (European Crohn’s and Colitis Organisation, United European Gastroenterology
Week and Digestive Disease Week). An update was performed up to 1 January 2018 for serological
biomarkers. We initially intended to search eight individual databases;1 however, because our search of
PubMed and EMBASE alone yielded nearly 30,000 citations, we decided that searching other databases
would have been unduly burdensome in return for identifying little useful additional research.
Eligibility criteria
l Target condition: primary studies had to report patients with proven new or established diagnoses
of Crohn’s disease for which at least one biomarker was used to predict subsequent development of
severe disease.
l Definition of Crohn’s disease: diagnosis used standard clinical, endoscopic and pathological criteria.
Studies reporting various severities were eligible if severe subgroups could be extracted.
l Participants: no age restriction was applied and paediatric studies (defined as aged < 16 years) were
noted for subgroup analysis. All ethnicities, races and religious groups were eligible.
TABLE 1 Search string used for the review





1 (crohn*) 41,703 60,679
2 Aggressiv* OR Sever* OR Disabling OR Montreal OR
Beaugerie OR Liege OR Flare OR Penetrat* OR Strictur* OR
Resection OR Surgical OR Surgery OR Stoma OR Failure OR
Active OR Adverse OR Harvey-Bradshaw OR HBI OR CDAI
OR index OR Perianal OR Complex
6,329,437 4,441,705
3 Biomark* OR Marker OR Assay OR Imaging OR Radiolog* OR
Genetic OR Examination OR Serum OR Blood OR Serolog*
OR Stool OR Faecal OR fecal OR feces OR faeces OR
Frequency OR Urin* OR Endoscop* OR histolog* OR
histopathol* OR antibod* OR age OR Smoking OR Test
9,823,770 5,491,617
4 course OR prognos* OR outcome OR cohort OR progres* OR
Predict* OR Risk* OR Outcome OR onset OR Biomarker* OR
Natural history OR Predict*[tiab] OR Predictive value of tests[mh]
OR Scor*[tiab] OR Observ*[tiab] OR Observer variation[mh]
OR risk prediction model[tiab] OR predictive model[tiab] OR
predictive equation[tiab] OR prediction model[tiab] OR risk
calculator[tiab] OR prediction rule[tiab] OR risk model[tiab]
OR statistical model[tiab] OR cox model[tiab] OR
multivariable[tiab]OR validate OR nomogram OR predictive
model OR validation OR prognostic model OR prognostic
scor* OR prognostic index OR predictor OR diagnos*
7,516,769 5,683,139
5 Review[Publication Type] OR Bibliography[Publication Type]
OR Editorial[Publication Type] OR Letter[Publication Type]
OR News[Publication Type]
2610 3843
6 1&2&3&4 13,905 22,498
7 6 NOT 5 11,295 18,655
REVIEW METHODS
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l Language: no language restriction was applied and translation was used where necessary.
l Inclusion criteria for biomarkers: to identify biomarkers with sufficient evidence, we stipulated that
potential individual predictors must have been reported in at least five individual studies. We made
an exception for ‘new but exceptionally promising predictors’, which were chosen by an expert panel
from a list of all candidates identified by the review. The panel were also asked to indicate any
predictor that was already in widespread use and which they deemed too important to be omitted
from the review.
l Definitions of severe disease and outcomes: no universally accepted definition of ‘severe’ Crohn’s
disease exists. Surgery is often used as a surrogate for severe disease but, at the same time, early
ileocolonic resection may be curative in some patients (and so these patients no longer have ‘severe’
disease). Immunomodulatory requirement as a surrogate for severe disease ignores the fact that
some patients achieve complete mucosal healing and avoid complications, and that these drugs
are used increasingly early in the disease trajectory. Although fistulae or penetrating disease form
the backbone of the severe ‘disease behaviour’ domains of the Montreal,16 Vienna16 and Paris17
classifications, perianal fistula is inconsistently considered, resulting in heterogeneous severity
within those exhibiting ‘complicated’ features.
To avoid discarding potentially important research, we included studies that used a broad range
of definitions. We also included studies that reported intestinal and perianal surgery [excluding
appendicectomy, non-inflammatory bowel disease (IBD) surgery and simple perianal drainage]. Studies
for which the end point was relapse or flare were excluded unless these aligned with our definitions
of severe disease. Likewise, treatment change alone did not meet our criteria given that this is not
necessarily associated with severe disease. We did not investigate lack of response to, for example,
anti-tumour necrosis factor (anti-TNF) therapy or antibody development because these are related to
treatment and are not in and of themselves surrogates for severe disease. Articles using treatment
costs as surrogate for disease severity were excluded. Table 2 shows varying definitions of severe
disease from Beaugerie et al.,18 Montreal behaviour classification,19 Liege criteria20 and the National
Institute for Health and Care Excellence (NICE) Technology Appraisal (TA) 187.21
We stipulated a minimum of 3 months between biomarker measurement and outcome measurement to
ensure that the biomarker was prognostic rather than diagnostic. Therefore, although studies exploring
development of severe disease following intestinal surgery were eligible (noting that surgery would
define severe disease in some classifications), prediction of early postoperative complications was
excluded. Likewise, because the stability of serological markers changes over disease course,22 we
required contemporaneous serum draw and outcome measurement.
TABLE 2 Definitions of ‘severe’ disease
Beaugerie et al.18 ‘disabling
disease’
Montreal behaviour
classification19 Liege criteria20 NICE TA18721
Three or more steroid courses
or steroid dependence;
hospitalisation for flare or
Crohn’s disease complications;
≥ 12 months of disabling symptoms
(nocturnal diarrhoea, urgency,
abdominal pain, fever, fatigue,
joint pain, uveitis or pyoderma);
need for immunosuppression;




(p = perianal modifier).
B2/B3 = severe Crohn’s
disease
Complex perianal disease;
any colonic resection; two
or more SB resections
(or a single SB resection of
≥ 50 cm); construction of a
definitive stoma
CDAI score of ≥ 300
or Harvey–Bradshaw
Index score of ≥ 8–9
CDAI, Crohn’s Disease Activity Index; SB, small bowel.
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Data extraction
Full-text articles were examined by Darren Boone and queries were initially raised with Lucinda Archer,
followed by other collaborators where necessary. Ultimately, Sue Mallett examined all full-text articles
selected for the review and verified data extraction, so that all results data were double screened and
extracted. Data were extracted into a data sheet that incorporated measures developed from the
CHARMS checklist15 and Prediction model Risk Of Bias Assessment Tool (PROBAST),23 with additional
fields specific to our review.
We extracted author, journal, design (e.g. cohort, randomised controlled trial, retrospective database),
methods, setting/context (organisation/service type, country), participants (including age, range, gender),
time since diagnosis (symptom duration and/or time since diagnosis for established disease), markers of
severe disease, symptom severity, disease location and burden, disease complications, Crohn’s activity
indices, surgical details, perianal disease and continence outcomes. In addition, we extracted data
specific to the prognostic marker investigated, including measurement (methods, frequency), adverse
events, reliability and reproducibility, and costs where available. We recorded study interventions and
outcomes (including definitions, thresholds for severity/remission and whether or not they were
prespecified) and median follow-up time with interquartile range (IQR).
For models, we documented study type (development, internal/external validation), included predictors
(including measurement methods, categorisation of continuous outcomes, blinding to outcome assessment
and predictor variables), sample size (number of participants with events and included in the modelling),
statistical modelling methods (including fitting, missing data treatment, methods to adjust for overfitting),
model performance (discrimination, calibration, sensitivity, specificity, net benefit, reclassification), model
estimates and 95% confidence intervals (CIs) (e.g. univariable unadjusted or adjusted estimates for
predictors, adjusted coefficients for predictors in multivariable models). Where available, we extracted
estimates with 95% CIs, including odds ratios (ORs), risk ratios and hazard ratios.
Risk-of-bias assessment
The risk of bias (ROB) for each included study was assessed via PROBAST.23 PROBAST has five
broad domains: patient selection, predictors, outcome, sample size and participant flow, and analysis.
Domains were combined to give an overall ROB.
Patient and public involvement
We included an ‘expert’ patient representative to help form our research proposal. The impact of
patient and public involvement (PPI) was minimal in the systematic review and meta-analysis phases of
this research given that data identification, extraction and analysis are largely independent of ‘opinion’.
However, as described in Chapter 7, we anticipate that PPI input will be vital for future research
because a non-medical perspective will be required to implement any model in daily clinical practice.
Weighting the presumed benefits of early biological treatment against the risk of side effects must be
considered against the predictive capabilities of the model, all from a patient perspective.
Statistical analysis
Where possible, participants with and without events (i.e. severe disease) were extracted into 2 × 2
contingency tables for each study. The number of studies and effect estimates for each predictor are
reported in Table 7. Studies were grouped for meta-analysis by their effect estimates (e.g. ORs and
hazard ratios). Meta-analysis was considered when there were three or more individual studies of a
biomarker from which data could be extracted using the same effect estimate.
REVIEW METHODS
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We looked for predictor association with subsequent severe disease rather than precise estimates of
strength or interpredictor comparison. We anticipated that varied designs would cause varied results;
therefore, meta-analysis reflects evidence across all studies which provided informative data regarding
specific situations, measurements and thresholds. Studies were grouped for meta-analysis by prediction
estimate type and, where sufficient, by definition of severe disease. We grouped studies that were
‘adequately adjusted’, which was defined by clearly reported adjustment factors including at least one
of the following confounders: age at diagnosis, perianal disease, steroids for first flare, disease location
and/or behaviour, smoking, surgery and family history. Forest plots present study results (see Figures 6–19).
Meta-analysis was considered for biomarkers with three or more studies using the same effect estimate;
excessive heterogeneity precluded combination. Each study was included once per meta-analysis; where
studies reported estimates at different definitions of severe disease, we selected the highest ranking
(order: surgery, B2/B3, B3, B2, other definition). To avoid confounding, B2 and B3 were identified as
predictors for which surgery was the outcome.We did not use B3 as a predictor for B3 or B2/B3 as
an outcome.
Random-effect inverse variance meta-analysis24 was used to pool ORs. Meta-analysis was performed
using ‘metan’ (Stata 14, StataCorp LP, TX, USA) because 2 × 2 tables were not always available.
Owing to the paucity of results for children alone, results were analysed across all ages, with age
groups indicated on forest plots.
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Chapter 4 Studies included in the reviews
This review is reported in accordance with Preferred Reporting Items for Systematic Reviews andMeta-Analyses (PRISMA) guidelines; the PRISMA flow chart is illustrated in Figure 1. In total,
29,947 abstracts were identified (PubMed, n = 11,292; EMBASE, n = 18,655). A total of 15,923
duplicates were removed and 14,024 abstracts were screened. After applying the eligibility criteria,
247 full-text articles were assessed, which included four of the biomarkers that were considered
essential by the expert panel. Ultimately, 71 articles were included in the review, which corresponded
to 56 non-overlapping patient cohorts. Reasons for exclusions are given in Figure 1.
Table 3 shows the predictors that were deemed important for meta-analysis by the expert panel.
Ultimately, this involved the addition of only one predictor: CRP. Nine predictors that were deemed
important were already included. Seven predictors that were deemed important yielded too few
individual studies to be viable for meta-analysis. For example, there were no prognostic studies of
faecal calprotectin. ‘Severe endoscopic lesions’ were deemed important but prognostic data were





Articles excluded after full-text review
(n = 176)
• Not predictive/prognostic, n = 57
• Did not meet severity criteria, n = 40
• Postoperative patients, n = 21
• Not in update, n = 20
• Biomarker not included, n = 9
• Cannot extract relevant data, n = 6
• Systematic review, n = 7
• Serum draw not at diagnosis, n = 5
• Overlapping data, n = 5
• Genome-wide study, n = 4
• Genetic subtypes only, n = 2
Full-text articles included after
expert panel added biomarkers
(n = 4)





Articles included in overview
(n = 71)
Identif ied during database search
(n = 29,947)
• PubMed, n = 11,292
• EMBASE, n = 18,655
Included in serological, urinary and
faecal biomarker review
(n = 13)
• Overlap with genetic review, n = 2
• Overlap with clinical review, n = 6
Included in clinical, radiological,
endoscopic and pathology review
(n = 58)
• Overlap with serological review, n = 6
• Overlap with genetic review, n = 11
Included in genetic review
(n = 17)
• Overlap with serological review, n = 2
• Overlap with clinical review, n = 11
• No overlap with serological or clinical, n = 6
FIGURE 1 The PRISMA flow chart. Some articles were included in more than one review. a, Hand-searching of
conference proceedings failed to yield any additional research.
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Ultimately, the number of papers included in the three reviews were as follows:
l general overview – 58 papers (including 11 contained in the genetic review and six in the
serological review)
l genetic review – 17 papers (including 11 contained in the general overview and two in the
serological review)
l serological review – 13 papers (including six contained in the general overview and two in the
genetic review).
TABLE 3 Predictors considered by the expert panel
Factor chosen by the experts Inclusion in overview
CRP Added
Azathioprine/biologicals Confounding treatment
Use of TPN Confounding treatment
Low adherence to medication Confounding treatment
Upper disease ‘Location’ included already
Bowel stenosis Included already
Internal fistula Included already
Stricture Included already
Development of strictures during
follow-up
Included already
Development of fistulae during
follow-up
Included already
Jejunal involvement Included already
ASCA-IgG Included already
ASCA-IgA Included already
Flares per year Insufficient to include (n = 0)
Faecal calprotectin Insufficient to include (n = 0)
Weight loss Insufficient to include (n = 1)
FOXO3a Insufficient to include (n = 1)
Systematic manifestations Insufficient to include (n = 2)
Severe endoscopic lesions Insufficient to include (n = 2)
Albumin Insufficient to include (n = 2)
Ethnic origin Insufficient to include and
diverse (n = 2)
ASCA, anti-Saccharomyces cerevisiae antibodies; IgA, immunoglobulin A;
IgG, immunoglobulin G; TPN, Total Parenteral Nutrition.
STUDIES INCLUDED IN THE REVIEWS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Chapter 5 Results of the reviews
Most of the studies were European (37/71, 52%), with 14 (20%) from the USA/Canada. A totalof 40 (56%) studies were multicentre (Table 4). In total, 36 (51%) studies were prospective,
33 (46%) were retrospective and two (3%) were unclear. Of 71 studies, 11 (16%) were paediatric only,
23 (32%) were adults only and 37 (52%) were mixed. Individual study characteristics are shown
in Table 4.
The recruitment dates varied (see Table 4), with 22 (31%) studies not reporting recruitment dates.
Follow-up also varied (median 8 years, IQR 5–10 years, range 0.8–18 years; Table 4). Nine studies allowed
extraction of prediction of severe disease events at multiple time points during follow-up.25–33 Studies
frequently presented several definitions of severe disease (Table 5).
TABLE 4 Overview of study characteristics
Study characteristic Total studies (N= 71)
Prospective study design (n = 36)
Prospective clinic 17
Prospective cohort 8
Prospective inception cohort 1
Prospective registry 10
Retrospective study design (n= 33)
Retrospective cohort 5
Retrospective clinic notes 17
Retrospective registry, databank 8
Retrospective case–control 3








Children and adults 37
Adults only 23
Recruitment dates reported 49
Number of patients, median (IQR) [range] 248 (159–555) [70–3118]
Number of events (severe disease), median (IQR) [range]a 76 (51–70) [14–981]
Follow-up (years), median (IQR) [range] 8 (5–10) [0.8–18]
IQR, interquartile range.
a Events calculated as mean of smallest and largest number of events per study.
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TABLE 5 Individual study characteristics
Study (first author
















Minimum Maximum Serology Genetic Clinical
Aldhous 200734 Scotland No Prospective
clinic
NR. Pre-2007 10 (0.3–55) Median (range) 274 105 113 Surgery,
B2/B3





2002–4 7.4 (SD 6.1) Mean (SD) 159 59 70 Surgery Adults No Yes No
Annese 200536 Italy Yes Prospective
cohort
NR. Pre-2005 Sporadic 7
(SD 4); familial
9 (SD 6)
Mean (SD) 316 87 151 Surgery Adults Yes Yes Yes
Beaugerie 200618 France No Retrospective
clinic records
1985–98 5 Fixed time period 1123 957 957 Other Both No No Yes
Brant 200337 USA Yes Retrospective
genetic cohort
NR. Pre-2003 B1 > 8 Minimum time
for B1
257 49 183 Surgery Adults No Yes Yes
Büning 200438 Germany No Prospective
clinic
NR. Pre-2004 6 (SD 7.0) Mean (SD) 180 51 51 Surgery Adults No Yes No
Charpentier 201439 France Yes Retrospective
from registry







NR. Pre-2006 10.5 (SD 6.4) Mean (SD) 80 38 38 B2/B3 Both No No Yes





1992–2012 7 (0–19) Median (range) 197 37 64 Surgery Both No No Yes




6.0 (IQR 5.6–8.1) Median (IQR) 100 21 24 Other Adults Yes No Yes
Cleynen 201343 EUa Yes Retrospective
hospital clinics
NR. Pre-2015 18 (10–62) Median (range) 1528 600 844 Surgery Both No Yes Yes
Degenhardt 201644 Germany No Retrospective
serum bank
2000–6 12 Median 70 20 20 Other Adults Yes No No
Dubinsky 200845 USA Yes Unclear. 21
hospital sites
NR. Pre-2008 2.5 (0.1 to 19.6) Median (range) 592 37 61 Surgery,
B2/B3
Children Yes No No
Goel 201346 India No Retrospective
clinic records
1995–2008 1.5 (0.1–16.5) Median (range) 223 73 93 Surgery,
B2/B3
Adults No No Yes
Gupta 200647 USA Yes Prospective
registry
2000–3 3.6 (SD 3.1) Mean (SD) 989 128 128 Surgery Children No No Yes
Henckaerts 200948 Belgium Yes Retrospective
registry
























































Minimum Maximum Serology Genetic Clinical
Israeli 201425 Canada No Retrospective
clinic records





2007–11 4.1 (1.8–5.4) Median (IQR) 112 29 29 Surgery Both Yes No Yes





2008–12 3.6 (3–4.3) Unclear 913 78 78 B2/B3 Children Yes No No
Kugathasan 200451 USA No Prospective
clinic
2003 3.3 (0.5–7.3) Mean (range) 138 49 49 B2/B3 Children No Yes No




1982–2008 7.1 (3.1–10.8) Median (unclear) 705 156 156 Surgery Both Yes No No
Lacher 201053 Germany No Prospective
clinic
2000–9 4.8 (0.3–13.1) Mean (range) 171 32 32 Surgery Children No Yes No
Laghi 200554 Italy No Retrospective
clinic records
NR. Pre-2005 10.1 (SD 8.1) Mean (SD) 193 145 187 Surgery Adults No Yes Yes
Lakatos 200555 Hungary Yes Prospective
cohort
2003–5 8.2 (3.2–13.2) Unclear 527 220 311 Surgery Adults No Yes No
Lakatos 200956 Hungary No Retrospective
clinic records
NR. Pre-2009 9.4 (1.9–16.9) Unclear 198 61 61 B2/B3 Adults No No Yes





2000–12 8 (5) Median (IQR) 79 22 34 Surgery,
other
Both No No Yes
Loly 200820 Belgium Yes Retrospective
clinic records
NR. Pre-2006 5 Minimum
follow-up
361 135 209 Other Both Yes No Yes
Louis 200326 France No Prospective
clinic
NR. Pre-2001 No information 90 18 53 B2/B3 Both Yes Yes Yes
Lovasz 201327 Hungary Yes Prospective
cohort
1977–2008 13.5 (6–19.5) Median (IQR) 287 33 110 B2/B3 Both No No Yes
Lunney 201558 Australia Yes Prospective
registry
1955–2012 9 (3–16) Median (IQR) 622 212 212 Surgery Both No No Yes
Malmborg 201559 Sweden Yes Retrospective
clinic records
1990–2007 8.8 (1.0–20.8) Median (range) 161 25 25 B2/B3/
surgery
Children No No Yes
Mazor 201160 Israel No Prospective
clinic
2000–10 12 Mean 146 65 65 B2/B3/
surgery
Both No No Yes



















































































































































































































































































































































TABLE 5 Individual study characteristics (continued )
Study (first author
















Minimum Maximum Serology Genetic Clinical
Nasir 201362 New Zealand Yes Retrospective
genetic
case–control
2003–13 9 Mean 503 240 240 Surgery Both No Yes Yes
Nasir 201363 New Zealand Yes Retrospective
genetic case
control
2003–13 9 Mean 503 240 240 Surgery Both No Yes Yes
Nunes 201364 Spain Yes Retrospective
registry
NR. 2006– 7.6 (3–13) Median (IQR) 3118 649 1313 Surgery,
B2
Adults No No Yes
Odes 200165 Israel Yes Prospective
cohort
NR. Pre-2000 7.1 (8.0) Mean (SD) 208 64 64 Surgery Adults No No Yes




2008–10 7.9 (6.8–8.0) Median (IQR) 339 59 59 Surgery Adults Yes No No
Oriuchi 200367 Japan No Retrospective
clinic records
1965–98 9.9 (7.5) Mean (SD) 146 44 44 Surgery Both No No Yes
Pandey 201568 Singapore Yes Retrospective
clinic records
1970–2013 7.3 (2.9–13.0) Median (range) 430 75 112 Surgery Both No No Yes
Papi 200569 Italy No Retrospective
clinic records
1993–2001 4.84 (1–23.2) Mean (range) 139 47 47 B3 Both No No Yes




1989–2010 5.4 Median 1403 471 471 Surgery Both No No Yes
Pigneur 201071 France Yes Retrospective
registry
2000–7 14.7 (10.8–45.2) Median (range) 618 374 374 Surgery Both No No Yes
Pittet 201328 Switzerland Yes Retrospective
clinic cohort
2006–13 > 10 Range 1026 83 463 Surgery Both No No Yes
Polito 199672 USA No Retrospective
clinic records
1985–91 14 Mean 555 85 334 Surgery Both No No Yes
Posovszky 201373 Germany No Prospective
clinic
NR. Pre-2013 15 (11) Mean (SD) 202 30 109 Surgery Both No Yes Yes
Protic 200874 Serbia No Prospective
clinic
2005–6 7 (0–30) Median (range) 131 33 81 Surgery Adults No Yes No
Renda 200875 Italy No Prospective
clinic
NR. Pre-2008 6.2 Median 182 110 110 Surgery Both No Yes Yes
Rieder 201076 Germany No Prospective
clinic
2000–6 0.8 (0.1–4.4) Median (IQR) 76 14 14 Surgery Adults Yes No No
Romberg-Camps
200977
The Netherlands Yes Prospective
registry
























































Minimum Maximum Serology Genetic Clinical
Ryan 201378 Canada Yes Prospective
registry
NR. Pre-2013 9.3 Median 86 21 100 Surgery Adults Yes No Yes
Sabate 200879 France No Prospective
clinic
2001–2 9.3 (7.7) Mean (SD) 225 83 83 B2 Adults No No Yes




251 40 69 Surgery Both No No Yes
Savoye 201281 France Yes Retrospective
registry
1988–2004 8 (7–12) Median (range) 309 115 237 Other Children No No Yes
Schaefer 201082 USA Yes Prospective
registry
2002–8 2.0 (1.8–2.3) Median (IQR) 845 57 72 Surgery Children No No Yes
Shaoul 200983 Israel Yes Prospective
clinic
NR. Pre-2009 4.9 (3.6) Mean (SD) 121 28 38 Surgery,
B2/B3
Children No Yes Yes
Siegel 201184 USA Yes Unclear. 21
hospital sites
NR. Pre-2008 2.8 (0.1–19.6) Median (range) 579 67 67 B2/B3 Children No No Yes
Siegel 201685 USA No Prospective
clinic
NR. Pre-2015 6.1 (0.3–15) Median (range) 243 142 142 B2/B3/
Surgery
Adults Yes No Yes
Smith 200429 Scotland No Prospective
clinic
NR. Pre-2004 11.5 (6.7–20) Median (IQR) 90 28 62 B2/B3 Adults No Yes Yes
Solberg 200786 Norway Yes Prospective
cohort
1990–4 10.3 (9–12) Median (range) 237 34 85 Surgery Both No No Yes




111 48 77 B2/B3/
surgery
Both No No Yes





2000–9 4 (1–21) Median (range) 167 42 79 Surgery Both No No Yes
Tarrant 200888 New Zealand Yes Retrospective
genetic
case–control
2003–5 6.5 (0.1–65) Median (range) 715 50 85 B2/B3 Both No No Yes
Thia 201089 USA Yes Retrospective
cohort
1970–2004 8.5 (0.01–36) Median (range) 248 50 139 B2/B3 Both No No Yes
van der Heide
200990
The Netherlands No Prospective
clinic
























































































































































































































































































































































TABLE 5 Individual study characteristics (continued )
Study (first author


























2003–4 7.7 (7.1–8.4) Median (IQR) 213 49 49 Surgery Both No No Yes




126 59 59 Surgery Both Yes No No





NR. Pre-2011 NR 207 147 166 Other Both No No Yes
Zabana 201333 Spain Yes Prospective
registry
1994–2003 7.6 (5.8–11.6) Median (IQR) 246 43 109 Surgery Both No No Yes
EU, European Union; NR, not reported; SD, standard deviation.
a Italy, France, the UK, Czechia, the Netherlands, Belgium, Spain and Germany.
Notes
Number of events refers to the number of patients with severe disease in a study. Maximum and minimum values are given as the same study may have different numbers of patients with severe disease for the different







































The forest plots for predictors indicate data characteristics, including event, paediatric versus adult
versus mixed population, and whether or not patients with severe disease were included at baseline.
For each predictor meta-analysis, we ensured that patients were included in analyses only once.
Figure 2 presents the ROB summarised across all studies.
Most of the studies were rated as having high ROB in at least one domain. Accordingly, ‘Overall ROB’
was rated as ‘high’ in 65 (92%) studies. Only three studies were rated as having ‘low’59,89,91 ROB
and three were rated as ‘unclear’.28,58,79 Concern regarding ‘Overall applicability’ was rated as ‘low’ or
‘unclear’, except for five studies.30,46,60,67,73 ROB and applicability for individual studies are presented in
Box 1 and Figures 3–5.
Overall, we identified 12 individual predictors eligible for inclusion: three serological, one genetic and
eight clinical. There were no radiological, endoscopic or histological predictors that met our criteria for
inclusion in the review.
Paediatric data are presented in the forest plots, but there were insufficient for subgroup analysis.
Table 6 shows the summary of findings across the meta-analyses performed.





Participant selection – applicability
Outcome – ROB
Predictors – ROB
Participant selection – ROB
Analysis





FIGURE 2 Risk of bias summarised across all studies.
BOX 1 Summary by domain of ROB and concerns relating to the applicability to the review question
Participant domain
Low ROB (n = 41) was determined when patients with severe disease could be excluded at baseline in data
extraction (n = 42) and the study design was not a case–control design (n = 68). Results are at ROB when
included patients have severe disease at baseline (n = 12 included; n = 16 unclear), as the results refer to a
mixture of prediction of severe disease and risk of diagnosis.
Fifty studies were rated as being of low concern for applicability. Twenty studies were rated as unclear
because of poor reporting and one study was rated as being of high concern owing to restricting enrolment
to Indian patients who had received previous antituberculous therapy.
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Predictor domain
Low ROB, for which measurement of predictors would not cause ROB, was identified in 69 studies. In two
studies,66,78 there is a potential ROB related to serological biomarker measurement because of the time of
serum collection.
Seventy studies were rated as being of low concern for predictor assessment applicability. One study78 was
rated as unclear for applicability because over 50% of patients had severe disease at enrolment when the
serum sample was taken.
Outcome domain
Forty-seven studies were rated as being at a low ROB. Studies were rated as at a high ROB when the
definition of severe disease did not correspond to our standard definitions, sometimes included steroid
dosing (n = 7), or where perianal surgery was included as surgery (n = 12).
Sixty-one studies were rated as being of low concern for outcome applicability, six were rated as being
unclear for applicability of outcome definitions because of poor reporting and four were rated as being of
high concern as a result of less relevant outcome definitions.
Flow and timing domain
Thirty-seven studies had a low ROB rating, based on an average time to event of 5–10 years and more
than 20 events in the analysis. A total of 31 studies were rated as being at high ROB (studies could be
rated as at high ROB for more than one reason): 30 studies because the average time to event was not
between 5 and 10 years, two studies, in addition, had fewer than 20 events; and one study’s time to event
was unclear as well as having fewer than 20 events. In three studies, the ROB was unclear as time to event
was unclear and there were more than 20 events in the analysis.
Applicability is not assessed for this domain.
Analysis domain
Thirty-one studies were rated as being at low ROB in the analysis because non-significant results were
reported for at least three standard predictors. Forty studies were rated at high ROB because fewer than
three standard predictors were reported with significant results. Standard predictors were defined as those
included in this overview.
Applicability is not assessed for this domain.
Overall
Three studies were rated as being at low ROB in all domains59,89,91 and in three the ROB was unclear.28,58,79
A total of 65 studies were rated as being at high ROB in at least one domain, mostly owing to ROB in
either flow and timing, or the analysis domain.
Forty-five studies were rated as having an overall low concern for applicability, with 21 having an unclear
rating and five having a high concern for applicability in at least one domain. The studies that were rated as
having a high concern were four studies with composite outcomes defined in a slightly non-standard way
and one study that enrolled Indian patients who had received antituberculous therapy only.
BOX 1 Summary by domain of ROB and concerns relating to the applicability to the review question (continued)
RESULTS OF THE REVIEWS
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FIGURE 3 Risk-of-bias and applicability concerns summary: review of author judgements regarding each domain for each
individual study in the clinical review. Orange circles indicate high ROB; blue circles indicate low ROB; purple circles
indicate uncertain ROB.
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Meta-analysis of clinical predictors
The following clinical predictors had prognostic data available from fewer than five studies and,
therefore, did not meet the inclusion criteria for the review: submucosal plexitis, fever, weight loss, poor
growth, medication, upper disease, Jewish ethnicity, joint problems, abdominal pain, oral contraception
(women), ethnic origin, systematic manifestations, systematic steroid use, azathioprine/biologicals,
granuloma, depression, cancer, diarrhoea, time to diagnosis from symptom onset, severe endoscopic
lesions, visceral fat area, rectal bleeding, fatigue, use of total parenteral nutrition, bowel stenosis,
internal fistula, alternative initial diagnosis, abscess, stricture, development of strictures during follow-up,
development of fistulae during follow-up, initial diagnosis at surgery, steroids per year, flares per year,
married/common law, low conscientiousness, high neuroticism, low adherence to medication, adverse
childhood experience, childhood sexual abuse, childhood physical abuse, high childhood adversity score,
asthma, eczema, glandular fever, kidney stones, liver disease, mental illness, bronchiectasis, tonsillectomy,
chole, grommet, immunised against measles, immunised against mumps, immunised against tuberculosis,
antibiotic consumption, medication consumption, breastfed, alcohol, vegetarian, takeaways, public
swimming, sand pit, farm, shared bedroom, continuous course, frequent relapse, symptoms at diagnosis,
– ? + + + ? – – – ?
? + + + + + – – – +
? ? – ? + + + + – ?
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FIGURE 4 Risk-of-bias and applicability concerns summary: review of author judgements regarding each domain for each
individual study in the serological review. Orange circles indicate high ROB; blue circles indicate low ROB; purple circles
indicate uncertain ROB.
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symptoms at 1 year, persistent mucosal erosions, jejunal involvement, Crohn’s Disease Activity Index
(CDAI), educational level, type of centre, nausea/vomiting, diabetes mellitus, coronary artery disease
and hypertension.
We were able to meta-analyse seven clinical markers from 58 studies. These were Montreal disease
behaviour, age, disease duration, disease location, smoking, sex and family history.
A meta-analysis of 12 studies (4376 participants, 1551 events) found that B2 stricturing, B3 fistulating
and either severe or disabling disease predicted severe disease more powerfully than B1 inflammation
alone (see Table 6 and Figure 6). B2 and B3 Montreal disease behaviours were the strongest predictors
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FIGURE 5 Risk-of-bias and applicability concerns summary: review of author judgements regarding each domain for each
individual study in the genetic review. Orange circles indicate high ROB; blue circles indicate low ROB; purple circles
indicate uncertain ROB.
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TABLE 6 Summary of findings table
Biomarker
Overall number of participants; events
expressed as minimum (studies)
Estimates
reporteda
Meta-analysis estimate (95% CI);
n studies Notes
ASCA 2559; 369 (10) l OR, n= 6
l HR, n= 2
l Adj HR, n = 1
l p-value, n= 2
OR 2.29 (1.31 to 3.99), 6 Five studies report increased severe
disease with presence of ASCA
Anti-CBir1 1878; 302 (5) l OR, n= 3
l HR, n= 2
OR 1.91 (0.85 to 4.31), 3 Two studies report increased risk with
presence of anti-CBir1
CRP 1170; 274 (3) l OR, n= 3 OR 1.17 (0.85 to 1.61), 3 Two studies report increased severe
disease with presence of CRP
NOD2 any variant 5526; 2683 (17) l OR, n= 16
l p-value, n= 1
Surgery OR 1.69 (1.43 to 2.00), 16 14 studies report increased severe disease
with presence of the NOD2 variant
Disease behaviour 8678; 3142 (16) l OR, n= 12
l Adj HR, n = 2
l p-value, n= 2
l B2: OR 4.09 (2.59 to 6.48), 11
l B3: OR 6.25 (3.68 to 10.63), 10
l B2/B3: OR 6.58 (4.18 to 10.38), 9
All studies report increased severe disease
with presence of B2, B3 or B2/B3
compared with B1
Age at diagnosis 19,623; 7010 (43) All age data:
l OR, n= 29
l Adj OR, n= 3
l HR, n= 5
l Adj HR, n = 2
l p-value, n= 6
l < 17 years to ≥ 17 years: OR 0.71
(0.52 to 0.98), 15
l < 17 years to 17–40 years: OR 0.59
(0.35 to 1.01), 8
l > 40 years to ≤ 40 years: OR 0.67
(0.38 to 1.17), 8
Age comparisons limited by data cut-off
points reported in studies. Aged < 17 years
at diagnosis has lower OR for severe
disease than that for older age
Duration of disease 8690; 1714 (14) All time points:
l OR, n= 22
l HR, n= 1
l p-value, n= 1
5 years: OR 3.48 (2.50 to 4.86), 7 Based on seven studies, risk of severe
disease increases with time from diagnosis
Location of disease l Any location: 10,877; 4193 (32)
l Colon only: 8584; 3500 (25)
l Colonic any: 70,571; 2999 (23)
l Colonic only: surgery OR 0.42
(0.31 to 0.58), 11
l Colonic any: surgery OR 0.50
(0.36 to 0.69), 11
Disease confined to the colon is a
predictor for less severe disease based on
surgical outcome than having disease at
any other location. Data synthesis only








































Overall number of participants; events
expressed as minimum (studies)
Estimates
reporteda
Meta-analysis estimate (95% CI);
n studies Notes
Perianal disease 13,483; 5510 (24) l OR, n= 13
l Adj OR, n= 1
l HR, n= 4
l Adj HR, n = 2
l p-value, n= 4
OR 1.84 (1.29 to 2.62); 13 10 studies report increased severe disease
with presence of perianal disease
Smoking 11,475; 5097 (34) l OR, n= 26
l Adj OR, n= 2
l HR, n= 1
l Adj HR, n = 1
l p-value, n= 4
OR 1.53 (1.30 to 1.79); 26 21 studies report increased severe disease
with current smoking
Sex 14,489; 5350 (35) l OR, n= 23
l Adj OR, n= 2
l HR, n= 5
l Adj HR, n = 1
l p-value, n= 4
OR 1.14 (0.98 to 1.31); 23 Sex has a non-significant association with
severe disease. Approximately half of
the studies favour men and half favour
women for lower risk
Family history
(Crohn’s disease or IBD)
5687; 1413 (18) l OR, n= 12
l Adj OR, n= 1
l HR, n= 1
l Adj HR, n = 1
l p-value, n= 3
OR 1.05 (0.81 to 1.36); 12 Family history has a non-significant
association with severe disease. Five
studies associated family history with
increased risk while seven associated no
family history with increased risk
Adj, adjusted; anti-CBir1, anti-flagellin antibody; ASCA, anti-Saccharomyces cerevisiae antibodies; HR, hazard ratio; NOD2, nucleotide-binding oligomerisation domain-containing protein 2.
a Hierarchy of estimates reported: OR, adj OR, HR and adj HR. For location, prediction groupings were restricted to colon only (disease located in colon only vs. disease not located in colon
only) and colon any (disease present in colon as well as potentially in other locations vs. disease not present in colon). For duration, disease results were reported for 1, 3 and 5 years.
Notes
l Review question: to overview evidence for key prediction biomarkers for development of severe Crohn’s disease.
l Patients/population: patients diagnosed with non-severe Crohn’s disease.
l Role: biomarkers measured or available prior to development of severe disease.
l Biomarkers: serological, genetic or clinical biomarkers.
l Definition of severe disease: severe disease according to intestinal surgery, Beaugerie et al.,18 Montreal behaviour,19 NICE TA definition,21 and Liege criteria.20 Exclude relapse or
disease flare.
l Studies: prospective cohort, retrospective case–control.
l Setting: mostly specialist IBD facilities, some specialist registries.
l ROB and applicability:
¢ Three studies had a low ROB in all domains (Malmborg et al.,59 Thia et al.,89 Vernier-Massouille et al.91) and three had an unclear ROB (Lunney et al.,58 Pittet et al.,28 Sabate et al.79)
A total of 65 studies were at a high ROB in at least one domain, mostly because of ROB in either flow and timing, or analysis domain. Thirty-one studies were rated with a high
ROB in the flow and timing domain; 30 were rated as at a high ROB as the average time to event was not between 5 and 10 years. Forty studies were at a high ROB as fewer than
three standard predictors were reported with significant results. Standard predictors were defined as those included in this overview.
¢ Forty-five studies had an overall low concern for applicability, with 21 having an unclear rating and five having a high concern for applicability in at least one domain. High















































































































































































































































































































































The participants’ age at diagnosis was examined in 43 studies (19,623 participants, 7010 events). Most
of the studies categorised age using the Montreal/Vienna thresholds, so data were greatest for three
groups: aged < 17 years, aged 17–40 years and aged > 40 years. Overall, diagnosis at < 17 years of age
was associated with a lower risk of severe Crohn’s disease than other ages (see Table 6 and Figures 7–9).
Disease duration was examined in 14 studies (8690 participants, 1714 events). A meta-analysis found
that increased duration of disease was associated with significant risk of severe disease at all durations


























































































































































































































11.16 (7.97 to 15.63)
2.46 (1.54 to 3.92)
8.01 (4.42 to 14.51)
5.83 (3.19 to 10.65)
1.93 (1.04 to 3.57)
2.30 (1.22 to 4.36)
3.09 (1.61 to 5.94)
5.64 (2.80 to 11.33)
1.39 (0.68 to 2.85)
8.83 (4.11 to 18.99)
4.02 (1.50 to 10.80)
4.09 (2.59 to 6.48)
 
12.44 (8.75 to 17.69)
2.36 (1.37 to 4.08)
3.21 (1.73 to 5.97)
4.20 (1.93 to 9.14)
5.75 (2.38 to 13.89)
22.06 (9.12 to 53.40)
12.61 (4.93 to 32.25)
7.29 (2.46 to 21.62)
4.02 (1.17 to 13.89)
4.26 (0.52 to 35.24)
6.25 (3.68 to 10.63)
 
11.74 (8.76 to 15.73)
2.42 (1.60 to 3.67)
4.44 (2.82 to 7.01)
11.08 (6.58 to 18.67)
5.94 (3.07 to 11.50)
10.09 (5.16 to 19.73)
13.85 (6.91 to 27.74)
4.70 (2.12 to 10.44)
4.02 (1.66 to 9.77)
































child P/P + D OR (95% CI)
Weight
(%)
Favours lower risk Favours higher risk
FIGURE 6 Forest plot of unadjusted ORs investigating Montreal disease behaviour as predictive of severe Crohn’s
disease. A, adult; AC, both adults and children; C, child; P, predictive effect only; P+D, predictive and diagnostic
effect combined.
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Disease location was examined in 32 studies (10,877 participants, 4193 events). Studies were diverse
regarding the segments and/or segment combinations described. We could analyse ‘colonic disease
alone’ and ‘any colonic disease’ versus other locations. Overall, colonic disease alone conferred
significantly lower surgery risk than other locations (OR 0.42, 95% CI 0.31 to 0.58) (see Table 6
and Figure 10).
Similarly, any colonic disease (23 studies, 7373 participants, 3086 events) predicted lower surgical or
B2/B3 risk than no colonic disease (see Table 6 and Figure 11).
0.1 1.0 10.0
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Subtotal (I2 = 68.8%, p = 0.000)









Subtotal (I2 = 59.2%, p = 0.016)






































































































































































































0.98 (0.70 to 1.38)
0.53 (0.37 to 0.75)
1.93 (1.20 to 3.08)
0.44 (0.25 to 0.79)
0.67 (0.38 to 1.20)
0.62 (0.31 to 1.25)
0.59 (0.29 to 1.19)
1.06 (0.50 to 2.25)
0.25 (0.11 to 0.57)
0.65 (0.29 to 1.46)
0.47 (0.17 to 1.28)
0.26 (0.07 to 0.91)
0.89 (0.22 to 3.54)
0.97 (0.23 to 4.04)
8.44 (1.54 to 46.27)
0.71 (0.52 to 0.98)
 
0.61 (0.33 to 1.13)
0.54 (0.26 to 1.09)
0.25 (0.11 to 0.56)
0.68 (0.29 to 1.57)
0.36 (0.13 to 1.00)
0.30 (0.08 to 1.06)
1.25 (0.31 to 5.10)
9.31 (1.67 to 51.99)
0.59 (0.5 to 1.01)
 
0.84 (0.39 to 1.80)
0.92 (0.39 to 2.17)
0.27 (0.11 to 0.64)
0.56 (0.20 to 1.57)
0.78 (0.26 to 2.33)
0.16 (0.04 to 0.62)
1.23 (0.30 to 5.00)
5.83 (0.87 to 38.94)





























child P/P + D OR (95% CI)
Weight
(%)
Favours lower risk Favours higher risk
FIGURE 7 Forest plot of unadjusted ORs investigating age and disease duration as predictive markers for severe Crohn’s
disease: age at diagnosis < 17 years compared with > 17 years, 17–40 years and > 40 years. A, adult; AC, both adults and
children; C, child; P, predictive effect only; P +D, predictive and diagnostic effect combined.
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Subtotal (I2 = 64.5%, p = 0.037)


























































1.71 (0.97 to 3.03)
2.14 (1.11 to 4.11)
1.39 (0.69 to 2.79)
0.82 (0.35 to 1.94)
1.54 (1.08 to 2.19)
 
1.09 (0.68 to 1.76)
0.34 (0.18 to 0.66)
0.53 (0.26 to 1.08)
0.63 (0.21 to 1.86)





   8.71
49.30







disease Adult/child P/P + D OR (95% CI)
Weight
(%)
Favours lower risk Favours higher risk
FIGURE 8 Forest plot of unadjusted ORs investigating age and disease duration as predictive markers for severe Crohn’s
disease: age at diagnosis 17–40 years compared with > 40 years. A, adult; AC, both adults and children; C, child;











































































































































































2.32 (1.78 to 3.02)
2.10 (1.35 to 3.27)
1.21 (0.74 to 1.98)
2.68 (1.50 to 4.80)
3.10 (1.65 to 5.81)









1.21 (0.92 to 1.59)
3.71 (2.57 to 5.36)
1.77 (1.19 to 2.61)
2.62 (1.68 to 4.08)
5.91 (3.26 to 10.73)
2.55 (1.48 to 4.37)
 
4.25 (3.30 to 5.47)
1.79 (1.39 to 2.31)
4.94 (3.44 to 7.09)
3.32 (2.28 to 4.83)
3.81 (2.50 to 5.80)
2.54 (1.60 to 4.03)
5.77 (3.33 to 10.01)











4.32 (3.41 to 5.46)
6.94 (4.86 to 9.92)
4.71 (3.10 to 7.14)
7.97 (4.62 to 13.73)
5.24 (2.72 to 10.10)
















child P/P + D OR (95% CI)
Weight
(%)
Favours lower risk Favours higher risk
FIGURE 9 Forest plot of unadjusted ORs investigating age and disease duration as predictive markers for severe Crohn’s
disease: duration of disease, prognostic studies only. A, adult; AC, both adults and children; C, child; P, predictive effect
only; P+D, predictive and diagnostic effect combined.
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Perianal disease (24 studies, 13,483 participants, 5510 events) was associated with a significantly
increased risk of subsequent severe disease overall (1.84 OR, 95% CI 1.29 to 2.62) (see Table 6
and Figure 12).
A total of 34 studies reported an association of smoking with severe disease (11,475 participants,
5097 events); a meta-analysis of 26 studies found that current smoking increased the risk of severe
Crohn’s disease significantly (OR 1.53, 95% CI 1.30 to 1.79) (see Table 6 and Figure 13).
Sex was examined in 35 studies (14,489 participants, 5350 events) and, overall, was not a significant
predictor of severe Crohn’s disease (see Table 6 and Figure 14).
Family history was examined in 18 studies (5687 participants, 1413 events). A meta-analysis found
no consistent direction and no significant association of family history and severe Crohn’s disease










































































































































































0.25 (0.16 to 0.40)
0.62 (0.35 to 1.09)
0.32 (0.18 to 0.58)
0.29 (0.15 to 0.55)
0.66 (0.33 to 1.31)
0.21 (0.10 to 0.43)
0.29 (0.14 to 0.59)
0.71 (0.29 to 1.69)
1.15 (0.47 to 2.82)
0.45 (0.18 to 1.12)
0.74 (0.27 to 2.00)
0.42 (0.31 to 0.58)
 
0.63 (0.34 to 1.15)
0.19 (0.10 to 0.35)
0.13 (0.05 to 0.29)
0.36 (0.16 to 0.84)
0.35 (0.15 to 0.82)
0.17 (0.05 to 0.51)










0.92 (0.64 to 1.32)
0.51 (0.32 to 0.83)
1.01 (0.51 to 2.02)
1.03 (0.42 to 2.55)
0.74 (0.19 to 2.97)


















child P/P + D OR (95% CI)
Weight
(%)
Favours lower risk Favours higher risk
FIGURE 10 Forest plot of unadjusted ORs investigating disease location as predictive of severe Crohn’s disease: colonic
disease only. A, adult; AC, both adults and children; C, child; P, predictive effect only; P+D, predictive and diagnostic
effect combined.
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0.40 (0.27 to 0.61)
0.30 (0.20 to 0.46)
0.37 (0.23 to 0.59)
0.99 (0.58 to 1.70)
0.42 (0.24 to 0.72)
0.56 (0.31 to 1.03)
1.12 (0.60 to 2.10)
0.17 (0.09 to 0.32)
0.57 (0.29 to 1.13)
0.54 (0.22 to 1.33)
1.13 (0.44 to 2.90)
0.50 (0.36 to 0.69)
 
0.24 (0.14 to 0.40)
0.24 (0.13 to 0.45)
0.38 (0.19 to 0.76)
0.81 (0.38 to 1.71)
0.23 (0.06 to 0.93)









1.65 (1.18 to 2.30)
1.19 (0.76 to 1.87)
6.57 (3.86 to 11.17)
2.34 (1.16 to 4.71)
2.05 (0.70 to 5.99)


















child P/P + D OR (95% CI)
Weight
(%)
Favours lower risk Favours higher risk
FIGURE 11 Forest plot of unadjusted ORs investigating disease location as predictive of severe Crohn’s disease: any




















Subtotal (I2 = 80.1%, p = 0.000)



















































































4.13 (2.29 to 7.45)
2.95 (1.59 to 5.48)
1.08 (0.52 to 2.26)
0.52 (0.22 to 1.20)
1.68 (0.69 to 4.06)
 
2.04 (1.54 to 2.70)
3.02 (2.03 to 4.50)
1.70 (1.11 to 2.60)
0.85 (0.54 to 1.34)
0.72 (0.42 to 1.24)
1.38 (0.69 to 2.74)
5.81 (2.64 to 12.78)
2.75 (1.12 to 6.69)
4.84 (1.11 to 21.07)






















child P/P + D OR (95% CI)
Weight
(%)
Favours lower risk Favours higher risk
FIGURE 12 Forest plot of unadjusted ORs investigating disease location as predictive of severe Crohn’s disease:
perianal disease. A, adult; AC, both adults and children; C, child; P, predictive effect only; P+D, predictive and diagnostic
effect combined.
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Meta-analysis of serological predictors
The following serological predictors had prognostic data available from fewer than five studies and,
therefore, were not subject to meta-analysis: thrombocytosis, faecal calprotectin, anti-Saccharomyces
cerevisiae antibodies (ASCA)-immunoglobulin (Ig)G, anti-CBir1, white blood cell (WBC), albumin,
erythrocyte sedimentation rate (ESR), platelets, anaemia, CRP, haematocrit, ASCA-IgA, ferritin, anti-Fla2,
anti-FlaX, anti-L IgA, anti-C IgA, anti-Saccharomyces chitobioside antibody (ACCA)-IgA, anti-Saccharomyces
laminaribioside antibody (ALCA)-IgG, anti-Saccharomyces mannobioside antibody (AMCA)-IgG and anti-I2.
Three serological markers (ASCA, anti-CBir1 and CRP) from 13 studies were meta-analysed. ASCA
and anti-CBir1 showed potential prognostic association; ASCA-positive patients had significantly
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0.97 (0.63 to 1.48)
1.70 (1.04 to 2.78)
1.01 (0.57 to 1.77)
2.55 (1.42 to 4.59)
1.86 (1.01 to 3.43)
1.16 (0.63 to 2.16)
1.71 (0.83 to 3.50)
3.09 (1.47 to 6.51)
2.53 (1.19 to 5.38)
1.98 (0.90 to 4.34)
6.25 (2.36 to 16.55)
0.97 (0.33 to 2.91)
1.75 (1.31 to 2.32)
 
1.52 (1.23 to 1.87)
1.44 (1.13 to 1.84)
1.35 (0.97 to 1.87)
1.31 (0.87 to 1.98)
1.15 (0.67 to 1.98)
1.67 (0.97 to 2.89)
1.69 (0.92 to 3.12)
1.03 (0.55 to 1.95)
1.61 (0.81 to 3.21)
0.80 (0.33 to 1.93)
5.14 (2.00 to 13.20)
0.92 (0.29 to 2.93)
0.24 (0.07 to 0.82)
4.66 (1.22 to 17.81)




























child P/P + D OR (95% CI)
Weight
(%)
Favours lower risk Favours higher risk
FIGURE 13 Forest plot of unadjusted ORs investigating smoking as a predictive marker for severe Crohn’s disease.
A, adult; AC, both adults and children; C, child; P, predictive effect only; P+D, predictive and diagnostic effect combined.
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1.68 (1.18 to 2.39)
1.13 (0.73 to 1.74)
0.65 (0.40 to 1.06)
0.59 (0.34 to 1.03)
1.24 (0.71 to 2.17)
1.42 (0.81 to 2.51)
0.80 (0.44 to 1.48)
2.42 (1.24 to 4.72)
0.89 (0.45 to 1.80)
0.78 (0.38 to 1.61)
0.68 (0.28 to 1.67)
1.04 (0.80 to 1.36)
 
0.96 (0.78 to 1.18)
1.07 (0.83 to 1.36)
1.00 (0.72 to 1.38)
0.88 (0.63 to 1.23)
0.96 (0.62 to 1.50)
1.72 (1.05 to 2.84)
1.19 (0.70 to 2.02)
2.84 (1.54 to 5.25)
1.30 (0.70 to 2.43)
1.93 (1.02 to 3.64)
1.26 (0.62 to 2.54)
1.49 (0.63 to 3.49)
























child P/P + D OR (95% CI)
Weight
(%)
Favours lower risk Favours higher risk
FIGURE 14 Forest plot of unadjusted ORs investigating sex as a predictive marker for severe Crohn’s disease. A, adult;


















Subtotal (I2 = 59.3%, p = 0.043)

















































































1.24 (0.60 to 2.53)
1.54 (0.69 to 3.44)
0.86 (0.37 to 2.01)
0.84 (0.35 to 2.01)
1.05 (0.42 to 2.60)
0.80 (0.31 to 2.05)
1.78 (0.46 to 6.87)
1.09 (0.78 to 1.51)
 
0.78 (0.47 to 1.28)
1.79 (1.06 to 3.01)
0.23 (0.05 to 1.01)
0.63 (0.08 to 5.00)
0.51 (0.02 to 11.51)
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FIGURE 15 Forest plot of unadjusted ORs investigating family history as a predictive marker for severe Crohn’s disease.
A, adult; AC, both adults and children; C, child; P, predictive effect only; P+D, predictive and diagnostic effect combined.
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Anti-CBir1 data were identified from five studies; meta-analysis from ORs did not reach significance
(see Table 6 and Figure 17), but additional evidence from hazard ratios indicated a significant
association between anti-CBir1 and severe Crohn’s disease (Table 7).
For CRP, data were identified from only three studies (the expert panel requested that CRP was
included) and the results found no significant predictive association of CRP and severe Crohn’s disease
(see Table 6 and Figure 18).
Meta-analysis of genetic predictors
The following genetic predictors had prognostic data available from fewer than five studies and,
therefore, were not subject to meta-analysis: LOC441108, TNFSF15, 5p13.1, NCF4, CX3CR1, JAK2,
SBNO2, ZPBP, PTGER4, PUS10, PRDM1, C13ORF31, SLC22A23, TAB2/MAP3K7IP2, PTPN22, ICOSLG,
STAT3, PTPN2, NKX2-3, POU2E1, U10, U7, AK097548, CDKAL1, HERC2, ATG4A, NALP3, IL21, CARD8,
nucleotide-binding oligomerisation domain-containing protein 2 (NOD2) – all 3 versus 0, TLR4 D299G,
FOXO3a, IBD5, DLG5, PAI-1, SMAD3, MMP, TIMP, ATG2A, FNBP1L and ATG4D.
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3.08 (1.91 to 4.94)
0.76 (0.32 to 1.81)
2.28 (0.79 to 6.61)
1.90 (0.63 to 5.67)
6.30 (1.73 to 22.90)
3.02 (0.77 to 11.90)











child P/P + D OR (95% CI)
Weight
(%)
FIGURE 16 Forest plot of unadjusted ORs investigating serological markers as predictors of severe Crohn’s disease:
ASCA. A, adult; AC, both adults and children; C, child; P, predictive effect only; P+D, predictive and diagnostic
effect combined.
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2.96 (1.84 to 4.77)
2.56 (1.00 to 6.54)
0.68 (0.23 to 2.00)











child P/P + D OR (95% CI)
Weight
(%)
FIGURE 17 Forest plot of unadjusted ORs investigating serological markers as predictors of severe Crohn’s disease:
anti-CBir1. A, adult; AC, both adults and children; C, child; P, predictive effect only; P+D, predictive and diagnostic
effect combined.
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ASCA Annese 200536 B2 316 NR p-value Yes 0.046
Dubinsky 200845 Surgery 592 61 HR Yes 3.2
(1.1 to 9.5)
Loly 200820 Other 73 NR p-value No NS
Siegel 201685 B2/B3/
surgery
243 142 HR Yes 1.42
(1.24 to 1.63)













Surgery 213 49 p-value No NR




Brant 200337 Surgery 257 183 p-value NR NR
Disease behaviour
(B2/B3)
Nunes 201364 Surgery 3118 1269 Adj HR Yes 4.42
(3.87 to 5)




Renda 200875 Surgery 182 110 HR No 0.9
(0.9 to 1.02)
at 1.5 years








161 25 HR No 0.72
(0.33 to 1.59)
Aldhous 200734 Surgery 251 113 Adj HR Yes 0.27
(0.16 to 0.45)




Papi 200569 B3 139 47 Adj HR No 0.7
(0.3 to 1.6)
Annese 200536 Surgery 316 87 p-value No NS
Perianal Annese 200536 Surgery 316 87 p-value No NS
Brant 200337 Surgery 257 183 p-value No NS
Chen 201541 Surgery 197 64 HR No 0.68
(0.32 to 1.42)
Law 201357 Other 79 34 p-value No NS
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Nasir 201362 Surgery 503 240 Adj OR Yes 2.84
(1.83 to 4.38)
Nunes 201364 Surgery 3201 1313 Adj HR Yes 1.32
(1.17 to 1.5)
Park 201370 Surgery 1403 471 Adj HR No 1.09
(0.91 to 1.32)
Ryan 201378 Surgery 182 77 p-value No 0.06
Siegel 201685 B2/B3/
surgery
243 142 HR No 0.86
(0.54 to 1.37)





Surgery 394 176 HR No 0.94
(0.53 to 1.65)
Smoking Lovasz 201327 B2/B3 287 110 HR No 1.48
(0.96 to 2.37)
Law 201357 Other 79 34 Adj HR Yes 4.68
(1.03 to 4.09)a
Brant 200337 Surgery 257 183 p-value No NS
Goel 201346 Surgery 223 73 p-value No > 0.3
Ryan 201378 Surgery 182 77 p-value No 0.05
Vester-Andersen
201492
Surgery 213 49 p-value No NS
Annese 200536 Surgery 316 87 Adj OR Yes 1.42
(1.06 to 1.88)
Papi 200569 B3 139 47 Adj OR No 1.2
(0.5 to 2.6)
Sex Nasir 201363 Surgery 503 240 Adj OR No 1.16
(0.77 to 1.74)
Papi 200569 B3 139 47 Adj OR No 1.67
(0.33 to 2.17)






161 25 HR No 0.59
(0.31 to 1.15)









Surgery 394 176 HR No 0.96
(0.71 to 1.3)
Aldhous 200734 B2/B3 274 105 Adj HR No 0.89
(0.6 to 1.3)
Annese 200536 Surgery 316 87 p-value No NS
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Of the genetic markers, results for NOD2 in at least one variant were reported in 17 studies, although
one study reported only p-values and was excluded from meta-analysis.83 Meta-analysis of 16 studies
(5407 participants, 2645 events) suggested higher risk of severe Crohn’s disease with a NOD2 variant
gene overall (OR 1.69, 95% CI 1.43 to 2.00); studies were a mix of prognosis and prognosis/diagnosis
(see Table 6 and Figure 19).
Identification of existing systematic reviews
During this review, we identified seven previous systematic reviews that investigated the association
of mostly serological and some genetic biomarkers with severe Crohn’s disease.94–100 Three of these
reviews95,99,100 did not separate primary studies of diagnosis and prognosis. One review95 identified two
studies of predictive biomarkers, one of which76 was also identified as the only prognostic study by a
second review.96 The remaining systematic review101 included three biomarker prediction studies, only
one of which met our inclusion criteria.
0.1 1.0 10.0

























0.98 (0.69 to 1.40)
1.69 (0.94 to 3.04)
1.18 (0.59 to 2.39)











child P/P + D OR (95% CI)
Weight
(%)
FIGURE 18 Forest plot of unadjusted ORs investigating serological markers as predictors of severe Crohn’s disease: CRP.
A, adult; AC, both adults and children; C, child; P, predictive effect only; P+D, predictive and diagnostic effect combined.















Brant 200337 Surgery 257 183 p-value NR NR
Law 201357 Other 79 34 p-value No NS
Ryan 201378 Surgery 182 77 p-value No NS






161 17 HR No 0.21
(0.03 to 1.56)
Aldhous 200734 Surgery 251 113 Adj HR No 1.06
(0.65 to 1.73)
Brant 200337 Surgery 257 183 p-value No NS
Ryan 201378 Surgery 182 77 p-value No NS
Tarrant 200888 B2/B3 715 85 p-value No NS
Adj, adjusted; HR, hazard ratio; MA, meta-analysis; NR, not reported; NS, not significant.
a 95% CI is as reported in the original publication.
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Search update: August 2020
To obtain an estimate of new data subsequent to our original search, we repeated the search at
the time of revising this monograph (August 2020). The search period was extended from 2016 to
17 August 2020, inclusive. The search string identified 4005 indexed studies from PubMed and 6878
studies from EMBASE. The researcher who performed the original search (Darren Boone) examined
the abstracts of all of these studies to identify studies of biomarkers with potentially prognostic
data. Ultimately, we identified 87 papers, seven of which were identified by our updated search
for serological markers that extended to 1 January 2018. That is, at the time of writing there were
potentially 80 additional papers that contained prognostic data relevant to our review question. All of
these papers were identified by the PubMed search; once duplicates had been removed, the EMBASE
search contributed no potentially relevant material. We identified no new biomarker that would satisfy
our a priori threshold for inclusion of reporting in five or more individual papers. Our original search
retained 29% of those papers subject to full-text review. A similar proportion applied here would
suggest that around 23 of these 80 papers would be suitable for inclusion, the large majority of which
examine phenotype and/or age and/or smoking. We are, therefore, as confident as we can be that at
the time of writing there are insufficient indexed data to alter our conclusions relating to genetic and
serological biomarkers, and that our meta-analytical data relating to clinical factors are likely to stand
unchanged. Table 8 details the additional potentially relevant research that was identified, which has
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1.35 (1.00 to 1.83)
2.12 (1.18 to 3.79)
1.13 (0.59 to 2.17)
2.32 (1.16 to 4.64)
0.60 (0.27 to 1.33)
2.75 (1.23 to 6.14)
0.89 (0.37 to 2.12)
1.44 (1.02 to 2.02)
 
1.82 (1.46 to 2.25)
1.65 (1.15 to 2.38)
1.60 (1.09 to 2.35)
2.36 (1.42 to 3.94)
1.33 (0.79 to 2.24)
1.35 (0.77 to 2.36)
3.54 (1.80 to 6.96)
2.62 (1.28 to 5.37)
2.20 (1.05 to 4.61)























child P/P + D OR (95% CI)
Weight
(%)
Favours lower risk Favours higher risk
FIGURE 19 Forest plot of unadjusted ORs investigating NOD2 (any variant) as a predictor of severe Crohn’s disease.
A, adult; AC, both adults and children; C, child; P, predictive effect only; P+D, predictive and diagnostic effect combined.
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TABLE 8 Summary of the potentially relevant research identified by an updated search performed in August 2020
Study (first author





Aaltonen 2019102 Risk factors for proctectomy in
consecutive Crohn’s colitis surgical




Aggarwal 2017103 Role of capsule endoscopy and fecal
biomarkers in small-bowel Crohn’s
disease to assess remission and
predict relapse
CDAI Calprotectin
Alexakis 2018104 Smoking status at diagnosis and
subsequent smoking cessation:
associations with corticosteroid
use and intestinal resection in
Crohn’s disease
Smoking
Arieira 2018105 Clinical course in Crohn’s disease:




Arora 2018106 Effect of oral tobacco use and
smoking on outcomes of Crohn’s
disease in India
Sex and smoking
Arora 2018107 Colonic Crohn’s disease is associated
with less aggressive disease course
than ileal or ileocolonic disease
Phenotype
Assa 2017108 Perianal pediatric Crohn disease is
associated with a distinct phenotype
and greater inflammatory burden
Phenotype and
perianal disease
Assa 2018109 The long-term predictive properties
of the Paris classification in paediatric




pANCA and ASCA in children with
IBD-unclassified, Crohn’s colitis,
and ulcerative colitis-A longitudinal




Bossuyt 2018111 Risk stratification for surgery in
stricturing ileal Crohn’s disease: the
BACARDI risk model
Phenotype CRP NOD2
Brückner 2018112 Incidence and risk factors for perianal
disease in pediatric Crohn disease




Buisson 2019113 Faecal calprotectin is a very reliable
tool to predict and monitor the risk of
relapse after therapeutic de-escalation
in patients with inflammatory bowel
diseases
Calprotectin
Burisch 2019114 Natural disease course of Crohn’s
disease during the first 5 years




Chaparro 2019115 Differences between childhood- and
adulthood-onset inflammatory bowel
disease: the CAROUSEL study from
GETECCU
Age at onset, sex,
EIMs, FHx and
smoking
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TABLE 8 Summary of the potentially relevant research identified by an updated search performed in August 2020
(continued )
Study (first author





Chaudhry 2017116 A fixed stricture on routine
cross-sectional imaging predicts
disease-related complications and






Chen 2017117 Performance of risk prediction for
inflammatory bowel disease based on
genotyping platform and genomic risk
score method
Age, age at diagnosis
and phenotype
GWAS
Chhaya 2016118 Emerging trends and risk factors for
perianal surgery in Crohn’s disease:
a 20-year national population-based
cohort study
Age, sex and location
Chun 2018119 Association of perianal fistulas with
clinical features and prognosis of




de Barros 2017120 Evolution of clinical behavior in
Crohn’s disease: factors associated




Dias 2017121 The risk of disabling, surgery and
reoperation in Crohn’s disease –
a decision tree-based approach
to prognosis
Phenotype
Dias 2017122 Development and validation of risk
matrices for Crohn’s disease outcomes





Diederen 2017123 Raised faecal calprotectin is
associated with subsequent
symptomatic relapse, in children and
adolescents with inflammatory bowel
disease in clinical remission
PCDAI CRP and
calprotectin
Dong 2019124 A novel surgical predictive model for
Chinese Crohn’s disease patients
Phenotype CRP, WBCs and
PLts
Foster 2019125 Consecutive faecal calprotectin
measurements for predicting relapse
in paediatric Crohn’s disease patients
PCDAI CRP and ESR
Fumery 2016126 Natural history of Crohn’s disease
in elderly patients diagnosed over
the age of 70 years: a population-
based study
Phenotype and EIMs
Fumery 2019127 Long-term outcome of paediatric-
onset Crohn’s disease: a population-
based cohort study
Phenotype
Gasparetto 2016128 Clinical course and outcomes of
diagnosing Inflammatory Bowel
Disease in children 10 years and
under: retrospective cohort study
from two tertiary centres in the
United Kingdom and in Italy
Age at onset, EIMs
and phenotype
continued
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TABLE 8 Summary of the potentially relevant research identified by an updated search performed in August 2020
(continued )
Study (first author





Guizzetti 2018129 Development of clinical prediction




Herman 2017130 The characteristics and long-term
outcomes of pediatric Crohn’s disease
patients with perianal disease
Age, sex and HBI Laboratory data
Herzog 2018131 Age at disease onset of inflammatory





Hou 2016132 Characteristics and behavior of
elderly-onset inflammatory bowel
disease: a multi-center US study
Age at onset
Huguet 2018133 Inflammatory bowel disease in
patients over the age of 70 years.
Does the disease duration influence
its behavior?
Age
Hwang 2017134 Influence of age at diagnosis on the
clinical characteristics of Crohn’s
disease in Korea: results from the
CONNECT study
Age at onset
Jeuring 2017135 Improvements in the long-term
outcome of Crohn’s disease over the
past two decades and the relation to
changes in medical management:
results from the population-based
IBDSL cohort
Phenotype
Jeuring 2016136 Epidemiology and long-term outcome
of inflammatory bowel disease
diagnosed at elderly age-an increasing
distinct entity?
Age and phenotype
Jones 2019137 Faecal calprotectin and magnetic
resonance enterography in ileal Crohn’s
disease: correlations between disease
activity and long-term follow-up
Age and MRI Calprotectin
Kaur 2016138 Perianal Crohn’s disease is associated
with distal colonic disease, stricturing
disease behaviour, IBD-associated
serologies and genetic variation in the
JAK-STAT pathway
Phenotype and FHx ASCA and
OmpC
Multiple Loci
Kayar 2019139 Risk factors associated with




Kim 2017140 Clinical characteristics and long-term
outcomes of paediatric Crohn’s
Disease: a single-centre experience
Age, sex, FHx and
phenotype
Kim 2017141 Incidence of and risk factors for free
bowel perforation in patients with
Crohn’s disease
Sex, age at diagnosis
and phenotype
Kim 2018142 The clinical characteristics and
prognosis of Crohn’s disease in
Korean patients showing proximal
small bowel involvement: results from
the CONNECT study
Phenotype
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TABLE 8 Summary of the potentially relevant research identified by an updated search performed in August 2020
(continued )
Study (first author





Kostas 2017143 Fecal calprotectin measurement is a
marker of short-term clinical outcome
and presence of mucosal healing




Kühn 2018144 [Risk factors for early surgery
and surgical complications in
Crohn’s disease]




Kunovsky 2019145 The role of the NOD2/CARD15 gene
in surgical treatment prediction in
patients with Crohn’s disease
NOD2
Kupka 2018146 Crohn’s disease – genetic factors and
progress of the disease
Phenotype NOD2
Kwapisz 2017147 The utility of fecal calprotectin in
predicting the need for escalation of
therapy in inflammatory bowel disease
Calprotectin
Levine 2020148 Complicated disease and response
to initial therapy predicts early
surgery in paediatric Crohn’s disease:





Liu 2018149 Lémann index at diagnosis predicts







C-reactive protein as a diagnostic and
prognostic factor in inflammatory
bowel diseases
Age CRP
Mañosa 2018151 Phenotype and natural history of
elderly onset inflammatory bowel
disease: a multicentre, case–control
study
Age at onset and
phenotype
Mosli 2018152 Risk stratification of patients with
Crohn’s disease: a retrospective
analysis of clinical decision-making
and its impact on long-term outcome
Age, smoking,
Montreal and age at
diagnosis
Müller 2016153 Baseline characteristics and disease





Naganuma 2016154 Endoscopic severity predicts long-
term prognosis in Crohn’s disease
patients with clinical remission
Phenotype CRP
Nahon 2016155 Diagnostic delay is associated with a
greater risk of early surgery in a French
cohort of Crohn’s disease patients
Age at onset and
phenotype
Ng 2016156 Early course of inflammatory bowel
disease in a population-based
inception cohort study from
8 countries in Asia and Australia
Phenotype
Nguyen 2017157 Risk of surgery and mortality in elderly-
onset inflammatory bowel disease:
a population-based cohort study
Age at onset and
phenotype
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TABLE 8 Summary of the potentially relevant research identified by an updated search performed in August 2020
(continued )
Study (first author





Pallotta 2018159 A risk score system to timely
manage treatment in Crohn’s disease:
a cohort study
Age, sex, phenotype,
CDAI and age at
diagnosis
CRP
Park 2019160 Update on the natural course of
fistulizing perianal Crohn’s disease in
a population-based cohort
Park 2017161 Development of a novel predictive
model for the clinical course of
Crohn’s disease: results from the
CONNECT study
Age and phenotype
Parker 2016162 Radiologic predictors of surgery in





DNA polymorphisms predict time to
progression from uncomplicated to
complicated Crohn’s disease
Multiple loci
Rinawi 2016164 Evolution of disease phenotype in
pediatric-onset Crohn’s disease after
more than 10 years follow up –
cohort study
Phenotype
Rispo 2018165 Combined endoscopic/sonographic-
based risk matrix model for predicting
one-year risk of surgery: a prospective




Rönnblom 2017166 Clinical course of Crohn’s disease
during the first 5 years. Results from a
population-based cohort in Sweden
(ICURE) diagnosed 2005–2009
Phenotype
Saad 2016167 Age of diagnosis is associated with
disease presentation and therapeutic
complications in patients with
Crohn’s disease
Age at onset and
phenotype
Sharma 2019168 Natural history of children with mild
Crohn’s disease
Phenotype
Smids 2017169 Candidate serum markers in early




Sollelis 2019170 Combined evaluation of biomarkers as




Song 2018171 Clinical characteristics and long-term
prognosis of elderly-onset Crohn’s
disease
Age at onset and
phenotype
Stallmach 2019172 Predictive parameters for the
clinical course of Crohn’s disease:
development of a simple and reliable
risk model




Sun 2019173 Clinical features and prognosis
of Crohn’s disease with upper
gastrointestinal tract phenotype in
Chinese patients
Age at onset and
phenotype
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TABLE 8 Summary of the potentially relevant research identified by an updated search performed in August 2020
(continued )
Study (first author





Szántó 2018174 Biological therapy and surgery rates in
inflammatory bowel diseases – data
analysis of almost 1000 patients from
a Hungarian tertiary IBD centre
Age at onset and
phenotype
Torres 2016175 Predicting outcomes to optimize
disease management in inflammatory
bowel diseases
Age at onset and
phenotype
Multiple Multiple loci
Wang 2018176 Study of disease phenotype and
its association with prognosis of






Wu 2019177 Serum protein biomarkers of fibrosis
aid in risk stratification of future




Ye 2017178 Fecal calprotectin is a strong
predictive marker of relapse in
Chinese patients with Crohn’s disease:
a two-year prospective study
Calprotectin
Zhao 2019179 A 10-year follow-up study of the
natural history of perianal Crohn’s
disease in a Danish population-based
inception cohort
Phenotype
Zhulina 2016180 The prognostic significance of faecal
calprotectin in patients with inactive
inflammatory bowel disease
Calprotectin
Ziv-Baran 2018181 Response to treatment is more
important than disease severity at
diagnosis for prediction of early






EIM, extra-intestinal manifestation; FHx, family history; GWAS, genome-wide association study; HBI, Harvey–Bradshaw
Index; MRI, magnetic resonance imaging; OmpC, outer membrane porin C; PCDAI, Paediatric Crohn’s disease activity
index; PLT, platelets.
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The research detailed in this monograph is a response to the NIHR HTA programme call of 2014,HTA 14/210, ‘Prognostic markers in early Crohn’s disease’. The outcomes stipulated by the HTA
programme in their commissioning brief were ‘[a]n overview of current evidence’ and ‘[a] signal as to
which biomarkers may be most useful’. Although a large amount of existing research has investigated
the potential of a multitude of biomarkers to predict severe Crohn’s disease, individual studies are
usually small, single centre and restricted to one or a handful of biomarkers. Furthermore, results from
individual studies often diverge, providing no clarity. The consequence is that individual clinicians
cannot synthesise these data in a way that is meaningful for individual patients. In response to the
brief, we have carried out a comprehensive overview across all biomarker types, the findings of which
are detailed in this report. Although we identified seven previous systematic reviews that investigated
associations between severe Crohn’s disease and mostly serological and some genetic biomarkers,
many confounded biomarker associations with both current disease (i.e. a diagnostic role) and future
disease (i.e. a prognostic or predictive role), with no distinction between the two roles.
To generate meaningful results, we stipulated an a priori criterion that excluded biomarkers with
insufficient evidence (defined by us as fewer than five component primary studies), and considered
meta-analysis only where data for an individual biomarker could be extracted from three or more
studies. Given the potential literature – we identified nearly 30,000 abstracts – we encountered
relatively few genuinely prognostic studies, that is studies that investigated the development of future
severe disease. We were surprised that common biomarkers, such as CRP, white blood cell count
and haemoglobin, were rarely investigated despite being in widespread clinical use. We found no
endoscopic, radiological or histopathological biomarkers that were sufficiently examined for meaningful
meta-analysis. Although we anticipated an inevitable delay between validation of new biomarkers and
subsequent prognostic studies, we were surprised that well-established biomarkers were poorly
researched. This dearth of research may reflect researcher preoccupation with novel biomarkers,
publication bias towards novel biomarkers or bias against studies finding no benefit.
Ultimately, across all biomarker types we identified only 71 individual studies with prognostic data,
representing just 56 non-overlapping patient cohorts. From these, this report presents a meta-analysis
of 11 potential predictors, of which eight displayed some evidence of predictive utility following meta-
analysis. We present results for NOD2 (any variant), the genetic predictor quoted in clinical guidelines
as being associated with an increased risk of severe disease. We present a meta-analysis of three
serological biomarkers, finding both ASCA-positive and anti-CBir1-positive patients to be at a higher
risk of severe disease. It may be that biomarker levels vary too widely to be useful; acute phase
reactant levels probably represent the patient status at diagnosis, for example during a flare. The levels
of antimicrobial antigens at subsequent times remain uncertain. Although studies with paired sera at
5-year intervals imply stability, others suggest that levels of antimicrobial antigens change with disease
progression and treatment. We excluded research without baseline serum draw. To have clinical utility,
biomarkers must be prognostic in early disease.
We meta-analysed seven clinical predictors: Montreal behaviour, age, disease duration, disease
location, smoking, sex and family history. Five of these showed prognostic potential (sex and family
history did not). The strongest association with subsequent severe disease across the entire review was
found for Montreal B2 and B3 categories, with ORs of 4.09 and 6.25, respectively. Meta-analysis also
suggested that increased risk of developing severe disease was associated with perianal disease, longer
disease duration and smoking. We found that the risk of subsequent severe disease was potentially
decreased in patients who were diagnosed at a younger age and in those with any colonic disease or
colonic disease alone.
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Our review does have limitations, the majority of which are contingent on the quality of the primary
component studies and difficulties with definitions of severe disease. As noted already, we found that
true prognostic research was relatively scarce and was often reported confounded with diagnosis.
Moreover, methods were heterogeneous and we were obliged to meta-analyse across different
methods of biomarker measurement, different positivity thresholds and different follow-up durations.
Such variability probably underlies the disparity between study effect estimates displayed, as seen,
for example, in the ASCA forest plot.
Because data were heterogeneous, we stress that interpretation of our findings should focus on which
biomarkers were found to have predictive potential rather than the precise strength of that prediction. Readers
should not draw conclusions regarding the effectiveness of different predictors given that our estimates are
based on results from different studies. Particularly for serological markers, the number and quality of studies
are presently such that findings from future studies will be important; the majority of genetic and serological
biomarkers that were identified were examined by insufficient studies for meaningful meta-analysis.
Furthermore, results from individual studies probably differ because of varying patient populations,
study designs or outcome definitions. For example, we were obliged to use a range of definitions for
‘severe’ disease because there is no single universally accepted/reported definition. Where the measure
is relatively inclusive, for example Beaugerie et al.,18 around 60% of patients will have ‘disabling disease’
within 5 years. Conversely, although the Liege criteria define severity more precisely,20 no article in our
review stated the extent of intestinal surgery with detail sufficient to allow post hoc classification;
single, early ileocaecal resection may be curative. Subsequently, only Loly et al.20 (who proposed the
Liege criteria) published data using this end point.
It is also possible that patients undergoing complex, expensive serological testing at diagnosis may be
spectrum-biased towards severe disease. It is self-evident that biomarkers predictive of future severe
disease have no clinical utility when such disease is established at diagnosis. For example, we were careful
not to use Montreal B3 at baseline to predict development of B3 disease. B1, B2 and B3 are used mostly
as predictors of surgery.We found that young age was not predictive of severe disease. However, children
often display a panenteric phenotype that precludes surgical therapy, even when disease is severe.
We found considerable ROB, mostly because of suspected reporting bias as studies reported fewer than
three standard predictors with non-significant results and results were not reported for standard follow-up
times. Accordingly, no results were available for follow-up extending 5 to 10 years. Our analyses included
some retrospective studies recruiting before 2004. Current treatment paradigms are evolving rapidly, and it
is unclear whether or not biomarkers will behave similarly pre- and post-biologic introduction; we present
individual study results with information sufficient for readers to explore this. Likewise, it was beyond our
remit to consider anti-TNF response/failure to respond/loss of response. Recent studies have found that this
in itself may identify patients destined to develop severe disease.182,183 Predictive studies of multigene assays
are currently under way, but we identified insufficient existing research for their inclusion in this review.
Owing to the large number of citations identified, we were unable to perform initial independent abstract
screening by two reviewers; Darren Boone screened all abstracts alone. However, any uncertainty
regarding eligibility, no matter how minor, was raised with Lucinda Archer (a statistician) initially and the
with other members of the team if any uncertainty persisted. However, it is possible that some relevant
data were discarded on the initial sift by using a single researcher. All full-text articles retrieved were
screened independently by Sue Mallett (the senior statistician) to verify that data extraction for meta-
analysis was correct, in particular to make the distinction between diagnostic and prognostic material.
This work has taken a considerable amount of time and resource, which was largely because of the
nature of the prognostic reviews in diagnosis. Diagnostic studies remain poorly and imprecisely
indexed in comparison with studies of therapeutic interventions. This problem is confounded further
when the aim is to separate diagnostic from prognostic information, which is often confounded within
DISCUSSION
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the same article (as explained elsewhere). The result is that search strings must be inclusive to avoid
missing important data, but this inflates the amount of primary research that must be examined.
We carried out an updated search in August 2020 to attempt to quantify the number of potentially
relevant data subsequent to our original search. We identified an additional 4005 indexed articles in
PubMed and 6878 in EMBASE, yielding 80 potentially relevant full-text papers. We estimate that
around 23 of these would ultimately yield useful prognostic data, the large majority dealing with
clinical biomarkers. Accordingly, we do not believe that our research has missed important serological
or genetic biomarker research and we believe that our findings are likely to stand overall.
In summary, we carried out a systematic review of biomarkers potentially predictive of subsequent
severe Crohn’ disease, across all biomarker types, and focused on those contained in clinical guidelines.
We found that prognostic research was heterogeneous and at a high ROB, and relatively few
biomarkers relevant to clinical guidelines were investigated sufficiently for meta-analysis. Of those that
were, we found evidence of prognostic potential for two serological (ASCA and anti-CBir1), one genetic
(NOD2) and five clinical biomarkers (Montreal behaviour, age, disease duration, disease location and
smoking). Considerably more prognostic research in this area is required, with methodological rigour,
informed by consensus agreement around definitions of severe disease and following the Transparent
Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD)
guidelines,184 so that study results can be used by other researchers.
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Chapter 7 Conclusions and
recommendations for future research
We can make two broad conclusions and recommendations that arise from the research presentedin this monograph. The first is that the quality and extent of prognostic research to predict future
disease severity is somewhat lacking. We recommend that funders consider commissioning studies that
are clearly prognostic and methodologically sound, and that adhere to established reporting guidelines
for prognostic research. Because of the evidence gaps we identified, any such research should
investigate all potentially important predictors, not just those that are perceived as ‘cutting-edge’
and/or ‘novel’.
The second recommendation stems from the predictors identified by our review and meta-analysis; in
the face of the limitations that we describe, we have identified a limited number of relatively easily
accessible predictors that could be combined and tested in a multivariable prognostic model. This model
would aim to accurately predict those patients with a new diagnosis of Crohn’s disease who are destined
to develop severe disease in the future, thereby facilitating individualised, early, targeted biological
therapy. At the time of writing, we are currently developing and validating such a model using historic
data obtained from the Royal Devon and Exeter NHS Trust; this work has been interrupted by the 2020
covid-19 pandemic that required clinical academics to return to full-time clinical work. It is our intention
to complete this work when possible. If that validation proves sufficiently promising, we will ask
that funders consider commissioning an external validation and/or clinical trial. Although the cleanest
methodology would be to randomise application of the predictive model, this may prove ethically
difficult given the widespread use of biological therapies currently. Due consideration should, therefore,
be given to use of historic databases.
As noted elsewhere, because the existing literature is deficient it is likely that we have ‘missed’ some
potentially important predictors simply because they have not been assessed sufficiently at the time of
writing. As a result, development of a multivariable model should be flexible and not be restricted to
the predictors identified by us. Development and validation could also incorporate multigene arrays,
which are garnering considerable current interest: their incremental benefit (or otherwise) can then
be quantified by their effect on prediction when added as one of the variables within an existing
prognostic model based on more easily accessible data.
The work described in this monograph has not had substantial PPI input because it is a review of
existing research performed by others. By contrast, we will seek PPI input from our expert patient
collaborator when we have completed our planned work on the predictive model. Specifically, to inform
clinical implementation of any model, we need to understand, from a patient perspective, how the
presumed benefits of early biological therapy might be weighed against potential harmful side effects.
These considerations must be made within the context of predictive accuracy, namely the degree to
which the model may deny biological therapy to some deserving patients while simultaneously
over-treating others.
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